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B cell lymphomas (BCL) are a group of heterogeneous hematological malignancies assumed 
to originate at different stages of lymphocyte development through different molecular genetic 
aberrations. Thus, different subtypes resemble lymphocytes at distinct differentiation stages and 
show peculiar clinic, morphologic, immunophenotypic and genetic features. Schematically, mature 
(non-lymphoblastic) BCL are proposed to be derived from pre-germinal center (GC), GC or post-GC B 
cells. In detail, mantle cell lymphoma (MCL) is considered a pre-GC neoplasm, follicular lymphoma 
(FL), Burkitt lymphoma (BL) and GC-type diffuse large B cell lymphoma (GCB-DLBCL) are of GC origin, 
whereas activated-type diffuse large B cell lymphoma (ABC-DLBCL), primary mediastinal B cell 
lymphoma (PMBL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), chronic 
lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL) appear to be derived from post 
GC B cells (figure 1).  
 
 
Figure 1. Origin of BCL with a list of the main molecular (red=gain of function and blue=loss of function) and 
immunohistochemical (green) biomarkers characteristic of each entity (modified from Sun 2016). 
 
Novel insights into the origin and biology of BCL have been achieved with the advance of 
new technologies, and a considerable number of molecular and immunohistochemical biomarkers 
that are related to alterations at the genetic, epigenetic, and protein level as well as the tumor 
microenvironment have become available nowadays (Shaffer 2012). They can be useful both at a 
speculative level to clarify details regarding the mechanisms underlying lymphomagenesis and for 
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practical purposes in the diagnostic workup, to predict the outcome and properly treat patients with 
personalized targeted therapies. For example, figure 1 summarizes the most important gain of 
function (red) and loss of function (blue) of molecular biomarkers involved in the various subtypes of 
BCL, as well as immunohistochemical markers (green) routinely used by pathologists in the 
differential diagnosis among different entities.  Despite a plethora of candidate biomarkers with 
potential clinical value have been suggested, it is crucial to understand when and how they can be 
integrated into the clinical setting, translating experimental results from bench to bedside, with the 
aim of improving patients’ care.  
Among BCL, DLBCL and FL are the most common types of non-Hodgkin lymphomas 
worldwide (WHO 2017) and still represent a challenge for both researchers and clinicians.  
 
 
 
Diffuse large B cell lymphoma (DLBCL) 
According to the latest revision of the WHO classification of tumours of the hematopoietic 
and lymphoid tissues, DLBCL is defined as diffuse proliferation of neoplastic B cells with a nuclear 
size greater than or equal to that of a histiocyte nucleus, or more than twice the size of a small 
lymphocyte (WHO 2017) (figure 2). 
 
 
Figure 2. DLBCL (Hematoxylin & Eosin X600). 
 
DLBCL represents the most common histological subtype of non-Hodgkin lymphoma (NHL), 
accounting for about 30% of adult NHL worldwide (WHO 2017). The median age of onset is 64 years, 
but any age can be affected and there is a slight male predominance (male-to-female ratio of 1.2:1) 
(WHO 2017).  
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Although DLBCL is an aggressive lymphoma with a median survival of less than one year if 
left untreated, it is a potentially curable disease. Since the 1970s, the CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisone) regimen has represented the standard therapy, with 50% of 
complete remissions (CR) and 30–40 % of long survivors (Rovira 2015). Since the early 2000’s, the 
addition of rituximab, the first approved anti-CD20 monoclonal antibody, to the chemotherapy has 
improved overall survival by approximately 20% (Feugier 2005, Sehn 2005, Bachy 2015). 
Overall, the disease exhibits a striking heterogeneity in terms of clinical presentation and 
outcome, morphology, immunophenotype and gene expression profiles. Some well-defined entities 
exhibiting peculiar clinico-biological characteristics have been recognized and classified as specific 
variants in the WHO classification (WHO 2017). In this scenario, the term DLBCL, Not Otherwise 
Specified (NOS) is used to collectively define a group of biologically and clinically heterogeneous 
cases not conforming to the defined subtypes and entities (figure 3).  
 
 
Figure 3. DLBCL subclassification according to the WHO classification of tumours of the hematopoietic and lymphoid tissues 
(from Swerdlow 2016).  
* Changes from the 2008 WHO classification 
 
Microarray studies have uncovered distinct molecular signatures in DLBCL that have unique 
biology and natural history (Alizadeh 2000, Rosenwald 2002, Monti 2005). They are characterized by 
distinct gene expression profiles either characteristic of normal GC B-cells or of activated blood 
memory B-cells. It is now well established that the cell of origin (COO) represents one of the major 
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sources of diversity in DLBCL, being associated with different molecular alterations and clinical 
evolution (Bea 2005, Tagawa 2005). In detail, patients with GCB-DLBCL have more favorable 
outcomes than those with ABC DLBCL when treated with standard R-CHOP immunochemotherapy 
(Alizadeh 2000, Rosenwald 2002). The original method used to define these entities performed GEP 
using microarrays on RNA extracted from frozen tissue (Lenz 2008). As the gold standard GEP 
methods are not readily accessible, being based on the availability of fresh frozen samples and 
microarray technology, immunohistochemistry (IHC)-based algorithm applicable in every laboratory 
to formalin fixed paraffin embedded (FFPE) tissues have been developed as a surrogate for GEP data 
(Hans 2004, Muris 2006, Natkunam 2008, Choi 2009, Nyman 2009). Among these classifiers, the 
most widely used is the Hans’ algorithm (Hans 2004), which is based on the combination of three 
markers: CD10, BCL6 and MUM1 (figure 4).  
 
 
Figure 4. Hans’ algorithm to determine the COO based on sequential evaluation of three immunohistochemical markers. 
 
However, it is evident that information obtained from complex gene-expression signatures on large 
numbers of genes cannot be reproduced using a very small number of antigens. Moreover, its 
intrinsic subjectivity and variability in scoring, lowers the reliability of such IHC-based methodology 
(Gutierrez-Garcia 2011, Gleeson 2015). More recently, a robust and highly accurate molecular assay 
for COO distinction using GEP techniques applicable to FFPE samples has been developed (Scott 
2014). The nCounter platform of NanoString Technologies (Seattle, WA, USA) is useful for the direct 
multiplex measurement of gene expression using FFPE samples, and numerous clinical research 
studies with this platform have been performed. Scott and coworkers have developed a 20-gene 
version of a NanoString code set for a COO typing assay of DLBCL named Lymph2Cx (Scott 2014). 
Fifteen genes, along with 5 housekeeping genes, were selected among 93 genes, based on their 
ability to accurately replicate the COO model originally proposed by Lenz (Lenz 2008). This assay 
brings to fruition the potential to use gene expression-based COO assignment in standard practice. 
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However, as the latest WHO update requires the identification of the COO and GEP is still not a 
routine clinical test, the use of IHC algorithms is considered acceptable (WHO 2017). 
Moreover, about 40% of DLBCL arise in non-lymphoid organs and are referred to as primary 
extranodal (EN) DLBCLs (Moller 2004, Vannata 2015, Vitolo 2016,). Some of them present distinct 
biology and clinical behavior and have been segregated out in the WHO classification (WHO 2017). 
These include primary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL, leg 
type, intravascular large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma and 
lymphomatoid granulomatosis. However, DLBCL can originate in almost every organ. Although 
several studies have been published, each addressing DLBCL arising in a different body site, the 
literature on primary EN lymphomas as a group is limited to a few papers. 
Finally, in the latest update of the WHO classification (WHO 2017), a new category named 
high-grade B-cell lymphoma (HGBL) has been introduced. This entity includes high grade lymphomas 
with MYC and BCL2 and/or BCL6 rearrangements and cases of diffuse aggressive B‐cell lymphoma 
with high grade features (such as intermediately sized blastoid cells, starry sky pattern, expression of 
CD10, variable BCL2, high proliferative fraction) that lack “double‐hit” genetic features and fall under 
the category of HGBL, NOS. The so called “double/triple-hit” (DH/TH) configuration of the former is 
strictly defined by the presence of rearrangements and breakpoints at the sites of both MYC and 
BCL2 and/or BCL6, as detected by cytogenetic techniques. MYC and BCL2 rearrangements may result 
in an overexpression of the related proteins, however, even if identification of the more common 
immunohistochemically defined double-expressor (DE) lymphomas is of interest, it is important to 
keep in mind that they only partially overlap with true DH/TH lymphomas. In detail, coexpression of 
BCL2 (≥50% of tumor cells) and MYC (≥40% of tumor cells) seems to be associated with worse 
prognosis, independent of other clinical risk factors in patients treated with standard 
immuno‐chemotherapy. For this reason, clinical trials have also been developed for DE cases (Green 
2012, Johnson 2012, Clark Schneider 2016). Nonetheless, they do not seem to be as aggressive as 
DH/TH HGBL, and there is less agreement on the clinical utility of their recognition (Swerdlow 2014). 
At the morphological level, HGBL-DH/TH may include, among others, all cases of otherwise typical 
DLBCL carrying a proven DH/TH (figure 5). Accordingly, it should be advisable to routinely perform 
FISH analysis in all DLBCL. If resources preclude this broad approach, as most DH/TH cases show a 
GCB phenotype and express MYC at immunohistochemistry, a limiting testing to this group 
represents an acceptable, despite inferior, alternative (Friedberg 2017, Sesques 2017).  
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Figure 5. HGBL-DH/TH categories according to WHO 2017 (from Friedberg 2017).  
 
In this scenario, a few months ago, the Italian Group of Haematopathology (GIE) proposed a 
practical workup for the diagnosis of aggressive mature B cell lymphomas. Based on a rational 
stepwise approach, the application of such algorithm allows the selection of cases deserving 
molecular analysis, with the aim of optimizing the use of costly and time-consuming techniques, and 
of assuring the optimal management of any patient (Di Napoli 2019). 
 
 
Primary EN DLBCL 
Due to the tendency of DLBCL to disseminate in both nodal and EN locations, the definition 
of a DLBCL as either primary nodal or EN has been a controversial issue, especially in advanced 
stages at presentation. Three alternative ways of defining EN lymphomas emerged when Krol and 
coworkers reviewed the available literature on the subject (Krol 2003) (figure 6). The same authors 
used data from a population-based NHL registry to illustrate the selection bias that is introduced 
when a strict definition of primary EN NHL, that excludes cases with disseminated disease, is used 
(Krol 2003). 
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Figure 6. Alternative ways of defining primary nodal and EN DLBCL, as reviewed in Krol 2003.  
 
Currently, it is accepted to operationally define as EN those lymphomas presenting as clinically 
dominant EN masses, with no, or only “minor”, nodal involvement at presentation (Zucca 1997, 
Vannata 2015). Another controversial issue is whether to consider peculiar body sites, namely the 
Waldeyer’s ring, the spleen and the bone marrow, as either nodal or EN. More commonly, cases 
arising in the Waldeyer’s ring and in the spleen are considered as primary nodal, whereas bone 
marrow is considered an EN location (López-Guillermo 2005, Kim 2011).  
The gastrointestinal (GI) tract is the most common EN site of presentation in DLBCL, with 10-
15% of all the DLBCL cases and 30-40% of all the EN cases, followed by the head and neck (H&N) 
district (Castillo 2014, Vannata 2015).  
Globally speaking, patients with EN disease present more frequently with early stage disease 
than those with nodal DLBCL (Møller 2004, Lal 2008, Castillo 2014). A potential explanation for this 
finding is that involvement of EN sites could be detected earlier based on signs and symptoms 
associated with the neoplastic mass effect. Results pertaining to other clinical characteristics, such 
as performance status and LDH levels are conflicting (Moller 2004, López-Guillermo 2005, Lal 2008). 
More interestingly, specific EN sites present distinct clinical and prognostic features. For example, 
lymphomas arising in the Waldeyer’s ring and in the digestive tract have been associated to early-
stage disease, no bone marrow infiltration, normal serum LDH, low- to low/intermediate-risk 
international prognostic index (IPI), and better outcome compared to DLBCL of other sites, though 
the outcome largely depends on other factors (López-Guillermo 2005, Lal 2008, de Leval 2012, Oh 
2013, Wang 2016). In contrast, other authors, found GI, together with pulmonary, hepatic and 
pancreatic DLBCL to carry a significantly worse prognosis (Castillo 2014), even at multivariate 
analysis. Finally, lymphomas arising at immune-privileged sites, namely the testes and the CNS, are 
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traditionally considered aggressive diseases requiring prompt diagnosis and specific therapeutic 
approaches (Vitolo 2008, Phillips 2014, Deng 2016, Grommes 2019). 
As far as the COO and the corresponding B cell differentiation markers are concerned, it has 
been hypothesized that DLBCL of primary nodal and EN origin might differ immunophenotypically. 
Data collected so far are often contradictory and difficult to compare, as most published works are 
based on small retrospective and heterogenous cohorts of patients. Moreover, although several 
studies have been published, each addressing DLBCL originating in a different EN body site, the 
literature on primary EN lymphomas as a group is limited to a few papers. The Korean group of Kim 
and coworkers didn’t find any significant difference in the frequencies of GCB and ABC subtypes or in 
CD10, BCL6 and MUM1 expression when analyzing a series of consecutive de-novo DLBCL arising in 
nodal and EN sites (Kim 2011). Only BCL2 expression differed between the two groups, being 
significantly less frequent in primary EN cases (Kim 2011). In contrast, other authors found BCL6 
expression to be more frequent in EN DLBCL, as a group, thain in nodal DLBCL (López-Guillermo 
2005). More commonly, specific EN sites were related to peculiar immunophenotypes. In detail, it 
has been reported that gastric DLBCL usually show a non-GCB profile, suggesting a relationship with 
marginal zone lymphoma, whereas intestinal DLBCL commonly belong to the GCB subset (Connor 
2007, Mitchell 2008). GC origin has been attributed to cervico-cephalic cases as well, especially when 
including DLBCL arising in the Waldeyer’s ring (López-Guillermo 2005, de Leval 2012, Wang 2016). On 
the other hand, DLBCL of the breast, of the testis and of the central nervous system have been 
associated to a non-GCB phenotype (Yoshida 2005, Al Abbadi 2006, Booman 2008, Gill 2014, Magnoli 
2015, Li 2017). Overall, it seems that peculiar immunophenotypes are not related to the mere nodal or 
EN origin, but rather to the specific site of presentation (Wang 2016). 
Peculiar biologic and molecular characteristics have been claimed for EN DLBCL, suggesting 
that these lymphomas might originate through different genetic pathways and even represent 
distinct pathological entities (Raghoebier 1991, Houldsworth 1996, Kramer 1998, Al-Humood 2011). 
Using conventional comparative genomic hybridization (CGH), some authors documented 
significantly distinct chromosomal aberrations between nodal and EN DLBCL (Al-Humood 2011), 
which appeared to be genuinely related to the site and not to the ABC/GCB subclassification, as 
assessed by Choi’s algorithm (Choi 2009). Moreover, it has been reported that BCL2/IGH 
rearrangement is more frequent in nodal DLBCL (Kramer 1998). By contrast, BCL6, MYC and REL 
molecular cytogenetic aberrations have been associated with an EN site of origin (Houldsworth 1996, 
Muramatsu 1996, Kramer 1998, Rao 1998). However, these single gene alterations have been found 
in relatively small and heterogeneous series and not widely confirmed (Houldsworth 2004, López-
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Guillermo 2005). Once again, it seems not the generic study of DLBCL as either nodal or EN to be 
more informative, but rather the analysis of the characteristics of each specific site. 
 
 
 
Follicular lymphoma (FL) 
FL is defined as a neoplasm composed of GC B cells (typically both centrocytes and 
centroblasts) with at least a focal follicular growth pattern (WHO 2017) (figure 7).  
As it has been demonstrated that the clinical aggressiveness of the lymphoma increases with 
the number of centroblasts, FL grading is based on the average number of large transformed cells in 
10-20 randomly selected neoplastic follicles at X400 high-power field (HPF) examination. A case with 
up to 5 centroblasts/HPF is grade 1; 6 to 15 centroblasts is grade 2; and greater than 15 centroblasts is 
grade 3 (Mann 1982). Grades 1 and 2 do not significantly differ in terms of clinical behavior and are 
now considered together as low grade. Grade 3 is further subdivided into 3A, with admixed 
centrocytes still present, and 3B, with solid sheets of centroblasts. Finally, diffuse areas composed 
solely or predominantly by centroblasts in FL of any grade have to be reported as DLBCL with FL 
(WHO 2017).  
The growth pattern can be predominantly follicular (>75% follicular), combined follicular and 
diffuse (25–75% follicular), or predominantly diffuse (<25% follicular). Diffuse areas are more common 
in grade 3 FL and predictive for worse prognosis (WHO 2017).  
Among clinical parameters, Ann Arbor stage and the Follicular Lymphoma International 
Prognostic Index (FLIPI) and FLIPI2 are well-known prognostic factors for patients with FL (Solal-
Celigny 2004, Federico 2009). 
 
 
 Figure 7. Left: FL with follicular growth pattern. Back to back neoplastic follicles with attenuated mantle zones lack cell 
polarization and tingible body macrophages (Hematoxylin & Eosin X100). Right: focus on centrocytes (small cleaved cells) 
and centroblasts (large noncleaved cells) (Hematoxylin & Eosin X600). 
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FL predominantly affects adults, with a median age of 55 to 59 years. It represents the most 
frequent form of NHL in Western countries and the second most common lymphoma worldwide 
(after DLBCL), accounting for 20% of all NHL (The Non-Hodgkin's Lymphoma Classification Project 
1997).  
Despite it follows a chronic indolent clinical course, FL remains incurable with standard 
therapies, being characterized by response to initial treatment with frequent relapses and shorter 
duration responses to salvage therapy. Management of FL has traditionally been based on a watch-
and-wait approach or chemotherapy. The introduction of the anti-CD20 monoclonal antibody 
rituximab has favorably impacted on prognosis, with median overall survival (OS) exceeding 12 years 
(Kahl 2016).  
In the last few years, it has become clear that FL represents a biologically complex and 
heterogenous disease (Magnoli 2019). Such aspect has been at least partly acknowledged by the 
inclusion of four clinicopathological variants of FL in the latest WHO update, namely in situ follicular 
neoplasm, duodenal-type FL, testicular FL, ad diffuse FL. In addition, separate entities, such as 
pediatric-type FL, large B-cell lymphoma with IRF4 rearrangement, and primary cutaneous follicle 
center lymphoma have been recognized (WHO 2017). However, besides these well-defined forms, 
other aspects of inter- and intra-tumor heterogeneity are evident at morphologic, 
immunophenotypic, genetic, and clinical levels. If correctly recognized and interpreted, these 
differences might represent the starting point for a tailored treatment. Particularly, the analysis of 
the genetic profile of tumor cells highlights important relationships between specific genetic lesions 
and tumor initiation, progression, and transformation. 
Green and coworkers have proposed an elegant multistep model to explain FL tumorigenesis 
in which founder mutations turn a non-malignant B cell clone into a premalignant tumor cell 
population, stable enough to acquire one or more secondary driver mutations, leading to an early 
malignant clone. Finally, tertiary mutations may either act as passenger or accelerator mutations, the 
latter providing a selective advantage to a progressed malignant subclone (Green 2013). In this 
context, the translocation (14;18)(q32;q21) is considered the genetic hallmark of FL and is reported 
with a prevalence of 85–90% in most published literature (WHO 2017). Subsequent aberrations of 
chromatin modifiers, genes involved in B-cell development, JAK-STAT and NF-κB signaling, as well as 
interactions with tumor microenvironment play a major role in the genesis, progression, and 
transformation of FL (Okosun 2014) (figure 8). 
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Figure 8. Genetic evolution of FL from early development to progression and transformation (from Green 2013). 
 
The t(14;18) seems to occur in bone marrow immature pre-B cells due to erroneous V(D)J 
recombination, resulting in constitutive expression of the BCL2 antiapoptotic protein. BCL2 
overexpressing B cells can survive irrespective of their B cell receptor (BCR) affinity, with the risk of 
acquiring additional genetic aberrations and a fully malignant phenotype (Sungalee 2014). 
Intriguingly, it has been demonstrated that both naïve and antigen-experienced t(14;18)+ B 
lymphocytes can be detected at low levels in the peripheral blood of up to 70% of healthy adults, 
most of which will never develop overt FL (Schüler 2009, Roulland 2006). Thus, the IGH-BCL2 
translocation has been considered necessary, although not sufficient to promote lymphomagenesis 
by itself.  
 
 
BCL2 negative FL 
As previously stated, the translocation (14;18)(q32;q21) is considered the genetic hallmark of 
FL (WHO 2017). However, some authors have observed a proportion of FL lacking t(14;18) as high as 
50% in their series, suggesting the existence of marked geographical differences and alternative 
mechanisms of genetic deregulation in BCL2- cases. In detail, reported detection rates are 
significantly lower in Far East and, to a less extent, European studies, compared to United States 
(US) series (Pezzella 1990, Albinger-Hegyi 2002, Biagi 2002, Payne 2011). It has been suggested that 
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these discrepancies may be technical rather than real, due to the use of methods unable to detect 
rearrangements involving BCL2 sequences outside of the major breakpoint region (MBR) and minor 
cluster region (mcr) (Aster 2002, Guo 2005). However, most false-negative results have been 
eliminated using more sensitive FISH methods, which are able to detect variant rearrangements that 
are missed by G-banding cytogenetics and PCR-based methods (Chang 2013). Some authors have 
pointed out that some cytogenetic changes may be missed by FISH analyses as well, such as 
translocations between BCL2 gene and unusual partner or cryptic translocations not detected by 
commercially available probes. However, this represents a rare occurrence (Godon 2003, Bentley 
2005). In a meta-analysis, Biagi and Seymour observed that the relative lower incidence of FL 
registered in Eastern populations seems not to depend on a lower frequency of BCL2 
rearrangements in healthy individuals, but rather on distinct molecular pathways operating in 
different geographical areas (Biagi 2002). On the other hand, some Asian researchers noted that the 
proportion of circulating lymphocytes carrying the t(14;18) in healthy subjects was much less 
prevalent than in the US, suggesting that ethnic disparity begins at a very early stage of disease 
development (Yakusawa 2001, Wu 2016). These findings do not exclude the original hypothesis that 
Western and Asian FLs represent heterogeneous entities, with different molecular pathogenesis. 
These discrepancies seem to be due more to lifestyle and environmental exposures rather than to 
ethnic background, as suggested by epidemiological data derived from Asian emigrants to the US 
and their descendants (Herrinton 1996, Wu 2019). Among others, high caloric intake, cigarette smoke 
and chemical agents such as pesticides, solvents, hair dyes, arsenic and compounds, asbestos, diesel 
fuel, nitrate, nitrite, or nitrosamine, have been called into question (Biagi 2002, Pan 2005, Richardson 
2008, Zhang 2008, Cocco 2010), but the precise nature of such putative factors is far from being 
elucidated. 
It is well-established that nodal grade 1–3A FLs without t(14;18) are morphologically 
indistinguishable from their translocated counterpart, but they are variably characterized by weak or 
loss of CD10 expression, increased Ki-67 labeling, higher MUM1 and granzyme B immunoreactivity 
and occasional CD23 positivity in lymphoma cells (Leich 2009). Moreover, this subset revealed a 
characteristic miRNA expression profile indicating a late GC B cell phenotype. Accordingly, GEP 
analyses documented an enrichment of GC B cell associated signatures in t(14;18)+ FL, whereas ABC-
like, NFkB, proliferation, and bystander cell signatures were enriched in negative cases (Leich 2011). 
Taken together, these findings demonstrate distinct molecular features between the two subsets, 
however, they do not shed light on the molecular pathogenesis of t(14;18)-negative FL. In this regard, 
it is important to remember that BCL2 protein overexpression has been recorded in a subset of FL 
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lacking t(14;18) (Falini 2002, Horsman 2003). Many of them showed extra copies of chromosome 18, 
which may implicate an increased dosage effect, and alternative mechanisms may operate in the 
remaining unamplified cases (Horsman 2003).  
In an attempt to identify pro-survival signals alternative to BCL2 overexpression, increased 
levels of some proteins such as Bcl-XL and activation of Akt/Bad pathway have been preferentially 
described in t(14;18)-negative FL (Ambrosini 1997, Zha 2004), despite no convincing deregulation of 
anti-apoptotic proteins alternative to BCL2 has been demonstrated so far.  
BCL6 gene encodes a transcriptional repressor whose oncogenic effect is well-recognized 
(Albagli-curiel 2003, Saito 2007). 3q27/BCL6 rearrangement has been variously reported as a 
transforming and proliferating stimulus alternative to the classic BCL2 deregulation in high grade FL 
(Katzenberger 2004, Guo 2005) or in low grade disease (Marafioti 2013). Others again have 
challenged its putative role as a crucial pathogenetic factor in BCL2-negative FL (Karube 2008, Leich 
2009).  
Katzenberger and coworkers identified a distinctive subtype of t(14;18)-negative FL, 
characterized by a predominantly diffuse growth pattern, localized involvement of inguinal lymph 
nodes and 1p36 deletion (Katzenberger 2009). Aberrations of this chromosomal region have been 
reported in BCL2- morphologically classical FL with a predominantly follicular growth pattern, but it 
should be noted that they represent one of the most common alteration in classical BCL2+ FL too 
(Kridel 2012, Launay 2012).  
Finally, an important player in clonal heterogeneity of FL is represented by activation-induced 
cytidine deaminase (AID), a gene whose product is required in the highly specialized GC 
microenvironment for both somatic hypermutation (SHM) and class switch recombination (CSR) to 
generate high affinity antibodies (Muramatsu 2000). In a small series of 2 and 3A FLs, Gagyi and 
coworkers found no differences in terms of ongoing SHM of the IGVH genes, aberrant SHM and AID 
expression between cases without BCL2 gene rearrangement and protein expression and 
lymphomas carrying the t(14;18). The authors hypothesize that, besides different molecular 
alterations at the starting point of lymphomagenesis, BCL2-positive and BCL2-negative FL represent 
the same entity sharing several molecular pathways, as in both cases the immunoglobulin receptor 
complex provides additional signals required for malignant transformation (Gagyi 2008). 
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Fluorescent in situ hybridization (FISH) 
FISH is a powerful technique firstly introduced in the early 1980's to detect and localize 
specific DNA sequences on chromosomes using fluorescent-labelled DNA probes (Langer-Safer PR 
1982). These probes are single-stranded DNA sequences, previously marked with fluorochromes, that 
are complementary to target regions, genes or genetic sequences of interest.  
FISH can be used both as a stand-alone technique on archived material, as it does not require 
cells in division (interphasic FISH), and in conjunction with chromosome banding to aid karyotype 
characterization. Interphasic FISH can be applied to different types of tumor nuclei, including 
imprinted nuclei, nuclei obtained from conventional cytogenetic procedures, frozen nuclei, paraffin-
embedded nuclei, and nuclei extracted from paraffin-embedded sections. As such, it may allow the 
simultaneous assessment of chromosomal aberrations, cellular phenotype and tissue morphology. 
Despite its high sensitivity and versatility, FISH is an indirect cytogenetic method and needs accurate 
controls to have adequate specificity. 
For the detection of chromosomal translocations, a variety of FISH probe strategies are 
available, each with its own limitations and benefits (Tibiletti 2007). Dual-color single-fusion probes 
are useful in detecting high percentages of cells harboring a specific chromosomal translocation. The 
DNA probe hybridization targets are located on one side of each of the two genetic breakpoints 
(generally one probe labeled in red and one in green). A nucleus lacking the translocation will exhibit 
a two-red, two-green signal pattern, whereas in a positive cell a yellow fusion in addition to single 
red and green signals corresponding to the normal alleles will be observed (figure 9A). Dual-color 
break-apart probes are designed on the opposite sites of a known genetic breakpoint which has 
multiple translocation partners. Each probe is labelled in a different color (generally red and green). 
In interphases of normal cells, two yellow fusion signals will appear, whereas following a 
translocation one separate green signal and one separate red signal, together with a preserved 
fusion signal will be observed (figure 9b). Finally, dual-color dual-fusion strategy is useful in detecting 
low numbers of nuclei harboring a simple balanced translocation. Two differently labelled probes 
(generally red and green) are designed to span the breakpoint of the genes involved in the 
translocation. Two fusion signals (derivative chromosomes), in addition to one green and one red 
signal (normal chromosomes), will be detected when a specific translocation involving both genes is 
present (figure 9c). 
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Figure 9. Probes strategies. Dual-color single-fusion (a); dual-color break-apart (b); dual-color dual-fusion (c). See text for 
explanations (from Tibiletti 2007). 
 
Commercial probes are currently available to detect chromosomal abnormalities relevant to 
the pathogenesis of lymphoproliferative disorders. For instance, the translocation (14;18)(q32;q21) is 
considered the genetic hallmark of FL, as previously stated. Moreover, about 20% to 30% of DLBCLs 
carry a t(14;18), these cases being predominantly centroblastic in morphology and belonging to the 
GCB subgroup (Copie-Bergman 2009, Tibiletti 2009, Akyurek 2012, Visco 2013). FISH analysis is clearly 
superior to PCR-based assays in investigating BCL2 translocations, due to breakpoints heterogeneity 
(Espinet 2008). Rearrangements of the 3q27 locus, where BCL6 maps, have been described in 
approximately 1/3 of DLBCL (Copie-Bergman 2009, Tibiletti 2009, Akyurek 2012) and have also been 
detected in FL (Díaz-Alderete 2008). MYC chromosomal aberrations have been observed in up to 15% 
of DLBCL, usually associated with complex karyotypes and poor outcome (Copie-Bergman 2009, 
Tibiletti 2009, Akyurek 2012, Visco 2013). Finally, the aforementioned DH/TH lymphomas are defined 
by the presence of rearrangements and breakpoints at the sites of both MYC and BCL2 and/or BCL6, 
as detected by cytogenetic techniques.  
The WHO classification of tumors of hematopoietic and lymphoid tissues emphasizes the 
importance of assessing chromosome abnormalities for accurate diagnosis, appropriate treatment 
and monitoring response to therapy. In the era of personalized medicine, patients are categorized 
into several groups based on their tumor characteristics. FISH represents a pivotal tool in identifying 
biomarkers that may predict the natural history of the disease and allow the administration of more 
precise therapy for different patients. 
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A plethora of immunohistochemical and molecular biomarkers have been identified and can 
be used nowadays both at a speculative level to clarify details regarding lymphomagenesis and for 
practical purposes in the diagnostic workup, to predict the outcome and properly treat patients with 
personalized target therapies. However, it is crucial to understand when and how they can be 
integrated into the clinical setting, translating experimental results from bench to bedside, with the 
aim of improving patients’ care.  
We decided to investigate the role of some of these biomarkers in two subtypes of NHL which 
still represent a challenge for both researchers and clinicians. 
The aim of the first part of my project was to evaluate the possible existence of differential 
immunophenotypic and genotypic profiles in DLBCLs arising at different primary EN sites.  In addition, 
survival analyses were performed in order to identify possibly significant prognostic variables. 
We next moved to FLs, with the aim of aim of testing the incidence of BCL2-negative cases in a 
series of Italian patients from the Insubric region. Moreover, we evaluated the clinico-pathological 
features and investigated alternative genetic aberrations of this subset. 
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Primary EN DLBCL 
 
Case selection 
One hundred and seventeen FFPE EN DLBCLs from 117 different patients were retrospectively 
collected from 6 institutes (Department of Pathology of the Ospedale di Circolo-University of Insubria, 
Varese, Italy; Surgical Pathology Division of the Ospedale A. Manzoni, Lecco, Italy; Department of 
Pathology of the Ospedale Valduce, Como, Italy; the Department of Pathology of the IRCCS 
MultiMedica, Milan, Italy; the Cantonal Institute of Pathology, Locarno, Switzerland; Centre de 
Pathologie, Strasbourg, France). The inclusion criterion was the diagnosis of DLBCL in an EN site, with 
no or only minor lymph node involvement at presentation (Zucca 1997, Vannata 2015). We excluded 
from further analyses cases with incomplete clinical data or scarce material, insufficient to undergo 
basic morphological, immunohistochemical and genetic characterization. As in case of a mediastinal 
mass most of the times we receive for the diagnosis small biopsy samples which do not satisfy such 
quantitative requirement, primary mediastinal LBCL are not present in our series. Moreover, cases 
primarily arising in the tonsils, in the spleen, in the bone marrow and in the thymus were excluded. 
Using these criteria, a total of 106 EN DLBCLs were included in our study.  
Primary sites were as follows: 44 gastrointestinal, 21 testicular, 13 central nervous system 
(CNS), 9 head and neck (H&N), 8 cutaneous and 11 DLBCLs arising at miscellaneous sites (Table 1). A 
subset of data regarding 18 out of the 21 testicular cases were previously included in two papers, 
recently published by our group (Bernasconi 2014, Magnoli 2015).  
 
 
Table 1. 106 EN-DLBCL detailed by site of origin. 
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All cases were histologically reviewed by two pathologists (FM and SU), and the morphological 
diagnosis of DLBCL was confirmed according to the criteria of the WHO classification of tumors of the 
hematopoietic and lymphoid tissue (WHO 2017).  
Clinical and follow-up data were obtained by consulting the files of the Oncology departments 
at the different Institutions. In detail, for all the patients we collected data regarding age at diagnosis, 
sex, the lymphoma site of origin, Ann Arbor stage, International Prognostic Index (IPI), therapy 
protocols, response to treatment and overall survival (OS), defined as the time from diagnosis to death 
from any cause. Moreover, survival results were compared to those we previously observed in a series 
of 71 primary nodal DLBCL (Uccella 2008). 
The study has been performed in compliance with the Helsinki Declaration and with policies 
approved by the Local Boards of Ethics. 
 
Immunohistochemical analysis 
Immunohistochemistry was performed on 3-μm-thick sections using the antibodies listed in 
table 2, either with an automated immunostainer (Benchmark XT; Ventana Medical Systems, Tucson, 
AZ) or manually.  
Staining results were evaluated semiquantitatively. In detail, a cutoff value of 30% of 
immunoreactive tumor cells was used to consider a case positive for CD10, BCL6 and MUM1, and to 
classify cases as GC or non-GC subtypes, as originally proposed by Hans and coworkers (Hans 2004).  
BCL2 and MYC expression were interpreted as positive if ≥50% and ≥40% of all lymphoma cells 
were immunoreactive, respectively. On the base of these results, we assigned each patient a double 
expressor score (DES) that ranged from 0 to 2, giving one point for each of the two markers expressed 
at or above the selected cutoff values. 
 
  
Table 2. List of the antibodies used in the immunohistochemical analyses. M: monoclonal; P: polyclonal. 
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FISH analysis 
In a subset of 58 cases including 15 testicular, 11 CNS, 14 gastrointestinal, 6 head and neck, 5 
cutaneous and 7 DLBCLs arising at miscellaneous EN sites, interphasic FISH was performed on sections 
used for conventional histologic examination (3–4 μm). Two slides respectively obtained before and 
after the one used for FISH analysis were hematoxylin-eosin stained to confirm the presence of an 
adequate neoplastic cellularity. Section thickness was established considering the cytoarchitectural 
organization and overlapping of nuclei in DLBCL. In our lab experience, 3 to 4 μm represents a good 
compromise between loss of evaluable spots due to nuclei truncation and overlapping.  
Probes for split-signal FISH targeting BCL2, BCL6, MYC, BCL10, CCND1, and MALT1 genes were 
provided by Dakocytomation Denmark A/S (Copenhagen, Denmark) and the FISH experiments were 
carried out as described elsewhere (Tibiletti 2004, Tibiletti 2009). Besides BCL2, BCL6 and MYC, whose 
importance in the genetic landscape of DLBCLs is well established, we speculatively decided to study 
BCL10, CCND1 and MALT1 genes similarly to what we did in a series of nodal DLBCL previously published 
by our group, due to their role in lymphomagenesis (Uccella 2008). Briefly, the analysis was performed 
using direct viewing on a standard fluorescence microscope (Leica DMRA) at 100x magnification. The 
presence of rearranged alleles was defined when the distance between red and green spots exceeded 
three times the fusion signal diameter.  
Each FISH experiment was analyzed blindly by two independent operators. In each case, more 
than 100 nuclei on PE sections were examined from at least 5 to 8 areas with well-preserved cellular 
and nuclear morphology. Only experiments with 100% hybridization efficiency were considered. The 
threshold values for the presence of specific chromosome rearrangements, trisomies and polysomies 
of the hybridized chromosome regions were evaluated for each probe on a panel of 10 PE sections of 
hyperplastic lymph nodes showing normal karyotypes by conventional cytogenetics. Reactive nodes 
were preferred to tonsils because the architectural organization of their nuclei is more similar to the 
one observed in DLBCL. The cutoff points were set as the mean value plus 3 standard deviations of 
nuclei showing split signals or 3, 4, and more than 4 spots. The standard deviation was calculated 
assuming a binomial distribution of the spots. Resulting cutoffs were 1,3%, 18,3%, 1,7% and 0,0% for 
chromosomal rearrangements, trisomies, tetrasomies and polysomies, respectively. 
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BCL2 negative FL 
 
Case selection 
Eighty-three consecutive nodal FLs diagnosed in our Pathology Department between 2013 and 
2016 were retrospectively collected. After excluding 7 cases with scarce material, a total of 76 FLs were 
further characterized in our study.  
All cases were histologically reviewed by two pathologists (FM and SU), and the morphological 
diagnosis of FL was confirmed according to the criteria of the WHO classification of tumors of the 
hematopoietic and lymphoid tissue (WHO 2017).  
Clinical and follow-up data were obtained by consulting the files of the Oncology department at our 
Institution. In detail, for all the patients we collected data regarding age at diagnosis, sex, the 
lymphoma site of origin, Ann Arbor stage, Follicular Lymphoma International Prognostic Index (FLIPI) 
and OS. Epidemiologic data on birthplace and migration flows were obtained from the registry offices 
at the municipalities of residence. 
The study has been performed in compliance with the Helsinki Declaration and with policies 
approved by the Local Boards of Ethics.  
 
Immunohistochemical analysis 
Immunohistochemistry was performed on 3-μm-thick sections using the antibodies listed in table 3, 
either with an automated immunostainer (Benchmark XT; Ventana Medical Systems, Tucson, AZ) or 
manually.  
 
 
Table 3. List of the antibodies used in the immunohistochemical analyses. M: monoclonal; P: polyclonal. 
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FISH analysis 
Interphasic FISH was performed on FFPE sections used for conventional histologic 
examination (3–4 μm), as described elsewhere (Tibiletti 2004, Tibiletti 2009).  
Commercial break apart probes targeting BCL2, IGH, BCL6 and MYC were provided by ZytoVision 
GmbH (Bremerhaven, Germany). Moreover, a subset of these cases was also investigated with an 
alternative BCL2 break apart probe provided by Vysis (Abbott Laboratories, Abbott Park, IL, Usa) at 
the Cantonal Institute of Pathology, Locarno, Switzerland.  
In a subset of 32 cases, FISH experiments were performed both on FFPE sections and on nuclei 
obtained from chromosome preparation of fresh lymphoma samples.  
Dual-color break-apart probes are designed on the opposite sites of a known genetic 
breakpoint which has multiple translocation partners. Each probe is labelled in a different color (red 
and green). In interphases of normal cells, two yellow fusion signals will appear, whereas following a 
translocation one separate green signal and one separate red signal, together with a preserved fusion 
signal will be observed (figure 9b, Introduction). 
Karyotype reconstruction analysis was performed in 11 FLs using direct chromosome 
preparations, as previously described by our group (Tibiletti 1996). A minimum of 10 metaphases were 
analyzed for each case and chromosome abnormalities were defined according to the most recent 
International System for Chromosome Nomenclature (ISCN) recommendations (ISCN 2016). When 
different tumor cell populations were identified, the chromosome complement of each population 
was described. 
 
 
Statistical analysis 
Associations in 2-way tables were tested for statistical significance using either the Χ2 test or 
Fisher exact test (2-tail), as appropriate.  
OS was defined as the time from the date of diagnosis until death from any cause or until the 
last date of follow-up. Patient survival was evaluated using the Kaplan-Meier method and statistically 
tested with the log-rank test.  
All analyses were performed using GraphPad Prism V5.0 software. A p value ≤0.05 was 
considered statistically significant. 
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Primary EN DLBCL 
 
 
Clinico-pathological results 
The summary of the clinico-pathological results is reported in table 4. The median age at 
diagnosis was 71 years (range 28-94 years). Sixty-two patients were males and 44 females.  
Most lymphomas in our series were confined to one side of the diaphragm and were 
classified as Ann Arbor stage I and II (59/83, 71.1%); in the remaining 24 cases (28.9%) more advanced 
disease was classified as stage III and IV. An International Prognostic Index (IPI) lower than 3 was 
observed in most cases (57/80, 71.25%), whereas high-intermediate and high scores were attributed 
to the remaining 23 patients (28.75%).  
Most patients received R-CHOP immunochemotherapy, alone or in combination with surgery 
(77/87, 88.5%), whereas only 10 were treated with either involved field radiotherapy or surgical 
resection alone. First line therapy achieved a complete remission in the majority of patients (71/80, 
88.75%). During the follow-up period, 22 of them (27.5%) experienced a relapsing disease, the highest 
rate of relapse being observed in intestinal DLBCLs (40%).  
Follow-up time ranged from 1 and 122 months. Survival data, available in 96 cases, showed 
that 45 (46.9%) patients were dead, while 51 (53.1%) were still alive at last follow up, with a median 
overall survival of 47.5 months from the first diagnosis. In detail, 40 out of 96 patients died of disease 
and 5 died of other cause. 
 
 
Patients’  
characteristics 
 
Whole 
series 
(n=106) 
Stomach 
(n=34) 
Intestine 
(n=10) 
H&N 
(n=9) 
CNS 
(n=13) 
Testis 
(n=21) 
Skin 
(n=8) 
Other 
sites 
(n=11) 
Age at diagnosis  
- Median age 
- Range 
 
71 
28-94 
 
69 
28-87 
 
75 
47-82 
 
82 
54-88 
 
66 
31-80 
 
69 
34-94 
 
75.5 
35-85 
 
66 
36-87 
Sex  
- Male 
- Female 
 
62 
44 
 
18 
16 
 
7 
3 
 
4 
5 
 
5 
8 
 
21 
0 
 
4 
4 
 
3 
8 
Stage  
- I-II 
- III-IV 
- Not known 
 
59 
24 
23 
 
23 
9 
2 
 
6 
1 
3 
 
3 
3 
3 
 
2 
3 
8 
 
12 
4 
5 
 
7 
0 
1 
 
6 
4 
1 
IPI  
- Low (0/1) 
- Low-intermediate (2) 
 
41 
16 
 
20 
7 
 
2 
1 
 
1 
2 
 
2 
2 
 
6 
2 
 
6 
1 
 
4 
1 
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- High-intermediate (3) 
- High (4) 
- Not known 
17 
6 
26 
4 
1 
2 
3 
0 
4 
2 
0 
4 
1 
0 
8 
2 
5 
6 
0 
0 
1 
5 
0 
1 
Therapy 
- Surgery only 
- CHT* only 
- Surgery + CHT* 
- RT# 
- Not known 
 
5 
47 
30 
5 
19 
 
0 
28 
5 
1 
0 
 
1 
1 
5 
1 
2 
 
0 
4 
1 
1 
3 
 
0 
2 
2 
1 
8 
 
4 
0 
12 
0 
5 
 
0 
5 
1 
1 
1 
 
0 
7 
4 
0 
0 
Response to first line therapy 
- Complete remission 
- Partial remission 
- Progression  
- Lost 
 
71 
2 
7 
26 
 
30 
1 
3 
0 
 
6 
0 
1 
3 
 
5 
0 
0 
4 
 
4 
0 
1 
8 
 
11 
0 
0 
10 
 
6 
1 
0 
1 
 
10 
0 
1 
0 
Follow-up: 
- Alive without disease 
- Alive with disease 
- Dead of disease 
- Dead of other cause 
- Not known 
 
Median OS (months) 
 
47 
4 
40 
5 
10 
 
47.5 
 
20 
2 
9 
2 
1 
 
57.5 
 
3 
1 
4 
0 
2 
 
25 
 
 
3 
0 
4 
0 
2 
 
27 
 
1 
0 
10 
0 
2 
 
19 
 
8 
0 
10 
1 
2 
 
21 
 
5 
1 
0 
0 
2 
 
63 
 
8 
0 
3 
0 
0 
 
72 
 
 
Table 4. Clinico-pathological features of 106 DLBCLs. CHT: chemotherapy; RT: radiotherapy. 
 *R-CHOP or R-CHOP- like regimens; Methotrexate for CNS DLBCL; #independently from other therapy 
 
Morphology, immunohistochemistry, COO and DES 
 
All cases showed a diffuse proliferation of large or medium-sized B lymphocytes, with a 
nuclear size greater than or equal to that of a histiocyte nucleus, or more than twice the size of a 
small lymphocyte. They were diagnosed as DLBCL, according to the typical histological and 
immunophenotypic features based on the WHO classification of Tumors of Haematopoietic and 
Lymphoid Tissue (WHO 2017), most of them belonging to the centroblastic variant (figure 10). 
 
 
Figure 10. DLBCL, centroblastic cytologic variant. The cells have vesicular chromatin and often membrane-bound nucleoli 
(Giemsa stain, X400). 
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Immunohistochemical results are detailed in table 5. Considering the antibodies included in 
Hans’ algorithm, CD10, BCL6 and MUM1 positivity was found in 20 (18.9%), 83 (78.3%) and 72 (67.9%) 
out of 106 cases, respectively. According to these results, we classified 41 (38.7%) DLBCLs as GC type 
and 65 (61.3%) as non-GC type and observed a significant predominance of the GC type in 
gastrointestinal tumors compared to other sites (p=0.008), whereas the non-GC type was more 
frequent in the immunological sanctuaries (CNS and testis) (p=0.0026). Most GC type lymphomas 
had a DES score of 0; conversely, most non-GC DLBCLs had an immunohistochemical score of 1 or 2 
(p=0.018). BCL2 expression was observed in half of our cases (54/106, 50.9%), with significantly 
different distribution according to the site of origin. In detail, all cervico-cephalic DLBCLs, three 
quarters of the testicular DLBCLs and half of the intestinal DLBCLs were BCL2 immunoreactive, 
whereas CNS, gastric and cutaneous cases showed BCL2 positivity in a lower percentage of cases 
(p=0.003). MYC expression was evaluable in a subset of 99 cases, 18 (18.2%) of which turned out to 
be positive. The statistical analysis demonstrated that lymphomas arising in the head and neck 
district had the highest expression of MYC protein compared to both the whole series and the other 
sites singularly (p<0.05). Ninety-nine of our 106 DLBCL were assessable for the DES index, as defined 
in the Material and Methods section. When grouping our cases according to the site of origin, we 
found a statistically significant difference in the distribution of the scores. Namely, DES 0 prevailed in 
gastrointestinal DLBCLs and DES 1 in lymphomas arising at immunological sanctuaries (CNS and 
testis), whereas most cases arising in the head and neck were attributed a DES 2 (p=0.02). 
 
 
Table 5. Immunohistochemical analysis. 
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FISH results 
 
Molecular cytogenetic results are detailed in table 6. Overall, BCL2, BCL6, MYC, CCND1, BCL10 
and MALT1 gene rearrangements, including translocations and inversions, were identified in 34 
(58.6%) of the 58 cases.  
According to the nomenclature previously proposed by our group (Tibiletti 2009), in half of 
the cases (17/34), gene rearrangements were present as major clones (more than 5% of rearranged 
cells) whereas in 13 out of 34 cases minor rearranged clones were identified (1.3-5% of rearranged 
cells). In the remaining 4 cases (11.8%), coexistence of major and minor clones was observed.  
BCL6 was the most commonly rearranged gene (39.5%), followed by MYC (20.9%), BCL2 (14%), 
CCND1 (11.6%), BCL10 (9.3%) and MALT1 (4.7%).  
The genes more involved in minor clones were BCL6 (6 cases) and MYC (4 cases).  
Multiple rearrangements were detected in 7 cases (20.6%): BCL6 and CCND1 (4 cases); BCL6 
and BCL10 (1 case); BCL6, BCL10 and MALT1 (1 case); BCL2, MALT1 and MYC (1 case). In most of DLBCLs 
with multiple rearrangements (4/7, 57.1%), one major and one or more minor populations were 
observed in the same sample.  
Considering the specific EN sites of origin, intestinal lymphomas showed the highest rate of 
gene rearrangements (89%), followed by H&N (67%), gastric (60%), testicular (60%), cutaneous (40%) 
and CNS (27%) DLBCLs. BCL6 was the most commonly rearranged gene in all sites, with exception of 
the GI tract and the skin, where MYC and BCL2 alterations prevailed, respectively. In DLBCLs arising in 
immune-privileged sites, i.e. CNS and testicular cases, we observed a higher frequency of minor 
rearranged clones than in other sites, with a trend towards statistical significance (p = 0,07).  
Interphasic FISH analysis with probes of different chromosome regions also provided data 
for chromosome assessment of DLBCL. Polysomies were observed for all investigated regions and, 
assuming that the presence of polysomy for more than 3 chromosomal regions suggests a polyploid 
chromosome assessment, 16 out of 58 (27.6%) EN DLBCLs resulted to be polyploid, whereas 42 
(72.4%) were classified as diploid. Polyploidy confirmed by FISH with centromeric probes coexisted 
with chromosome rearrangements in 10/16 cases. Interestingly, gene amplification was observed in 3 
DLBCLs arising in the GI tract and involved MYC alone in 2 cases and both MYC and MALT1 in one case. 
Two out of 3 MYC amplified cases also revealed a concomitant MYC rearrangement (figure 11). 
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Figure 11. FISH analysis of case #38 using MYC break-apart probe (a) and dual color MYC (green)/chromosome 8 centromere 
(red) probe (b and c).  These analyses demonstrated: a) MYC rearrangement and concomitant 5’ MYC region deletion, b and 
c) Amplification of MYC region (green signals) compared to chromosome 8 centromere (red signals).
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Case 
n° 
Site 
FISH analysis Immunohistochemical analysis 
Translocations Poliploidy Amplifications 
Bcl-2 
(50%) 
Myc 
[%] 
DES 
CD10 
(30%) 
Bcl-6 
(30%) 
MUM1 
(30%) 
HANS 
1 CNS NO YES NO - 25% 0 + + + GC 
2 CNS NO NO NO - - 0 + + + GC 
3 CNS NO NO NO - 20% 0 - + + nonGC 
4 CNS BCL6 (sc) NO NO + 30% 1 - - + nonGC 
5 CNS NO NO NO - 10% 0 - + + nonGC 
6 CNS NO YES NO - 30% 0 - + + nonGC 
7 CNS NO NO NO + 60% 2 - + + nonGC 
8 CNS NO NO NO + - 1 - + + nonGC 
9 CNS NO NO NO - - 0 - - - nonGC 
10 CNS 
BCL6, CCND1 
(sc) 
NO NO - 5% 0 - + + nonGC 
11 CNS BCL10 (sc) NO NO - 30% 0 - + + nonGC 
12 Testis  
BCL6 (sc), 
BCL10, 
MALT1 (sc) 
YES NO + 30% 1 - + + nonGC 
13 Testis  BCL6 (sc) NO NO + 15% 1 - + + nonGC 
14 Testis MYC (sc) YES NO + 20% 1 - + + nonGC 
15 Testis NO NO NO + - 1 - + + nonGC 
16 Testis NO NO NO - 20% 0 - - + nonGC 
17 Testis BCL6 NO NO + 30% 1 - + + nonGC 
18 Testis BCL6 YES NO + - 1 - - + nonGC 
19 Testis BCL6 (sc) YES NO + - 1 - + + nonGC 
20 Testis NO YES NO + - 1 - - + nonGC 
21 Testis BCL2 (sc) NO NO + 40% 2 + + + GC 
22 Testis NO NO NO + - 1 - + + nonGC 
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23 Testis BCL6 NO NO - - 0 + + + GC 
24 Testis NO NO NO + 60% 2 - - + nonGC 
25 Testis NO NO NO + - 1 - - + nonGC 
26 Testis 
BCL2, MALT 
(sc), MYC (sc) 
YES NO + 5% 1 - + + nonGC 
27 Stomach  MYC NO NO + 60% 2 + - + GC 
28 Stomach 
BCL6, BCL10 
(sc) 
NO NO + - 1 - + + nonGC 
29 Stomach NO NO NO + 10% 1 - - + nonGC 
30 Stomach BCL6, CCND1 YES MYC - - 0 - + + nonGC 
31 Stomach NO NO NO + - 1 - + + nonGC 
32 Small bowel BCL10 (sc) YES NO + - 1 + - - GC 
33 Small bowel MYC (sc) NO NO - 80% 1 + + + GC 
34 Small bowel MYC NO MYC + 80% 2 + + + GC 
35 Small bowel BCL2 NO NO + 10% 1 + + - GC 
36 Small bowel 
BCL6, CCND1 
(inv) 
NO NO - - 0 - + + nonGC 
37 Colon BCL6 NO NO - - 0 - + - GC 
38 Colon MYC NO MYC, MALT - - 0 + + + GC 
39 Colon MYC (sc) NO NO + 30% 1 - + + nonGC 
40 Colon NO NO NO - 20% 0 + + - GC 
41 Skin NO YES NO - 40% 1 - + - GC 
42 Skin BCL2 NO NO - - 0 + + - GC 
43 Skin NO NO NO - 7% 0 - + + nonGC 
44 Skin NO NO NO + - 1 + + + GC 
45 Skin  BCL2 (sc) YES NO - - 0 + + + GC 
46 H&N NO YES NO + 70% 2 - - + nonGC 
47 H&N CCND1 (sc) YES NO + 40% 2 - - + nonGC 
48 H&N BCL6 NO NO + 30% 1 - + + nonGC 
49 H&N MYC NO NO + 40% 2 - + + nonGC 
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50 H&N NO YES NO + 50% 2 - + + nonGC 
51 H&N BCL6 NO NO + - 1 - + + nonGC 
52 Adrenal gland BCL6 NO NO + - 1 - + + nonGC 
53 Bone BCL2 NO NO + 25% 1 + + - GC 
54 Mammary gland BCL6 (sc) YES NO + - 1 - + - GC 
55 Retroperitoneum NO NO NO - - 0 - + - GC 
56 Thyroid gland MYC NO NO - 70% 1 + + - GC 
57 Thyroid gland 
BCL6 (sc), 
CCND1 (sc) 
NO NO + - 1 - + + nonGC 
58 Urinary bladder NO NO NO + - 1 - + + nonGC 
                                
Table 6. FISH analyses as compared with immunohistochemical results.  
SC: small clone. 
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Comparison between immunophenotypic profile and 
chromosomal rearrangements  
In the cytogenetically investigated subset of EN DLBCLs, the immunohistochemical algorithm 
identified 38 DLBCLs with the non-GC phenotype and 20 with the GC phenotype. Overall, the number 
of gene rearrangements detected in the two groups was not statistically different (p = 0.27). Multiple 
rearrangements occurred in a significantly higher proportion of non-GC DLBCLs (p = 0.03). BCL6 
rearrangements were significantly more frequent in non-GC than in GC lymphomas (p = 0.01). 
Conversely, BCL2 rearrangements occurred in a higher portion of the GC cases, with a trend towards 
statistical significance (p = 0.06). No significant differences were found regarding CCND1, MALT1, 
BCL10 and MYC, even though CCND1 and MALT1 alterations were exclusive of non-GC cases (5 and 2 
cases, respectively). All four cases displaying the coexistence of major and minor clones belonged to 
the non-GC group.  
As far as BCL2 was concerned, 34 (60.7%) out of 56 DLBCLs showed immunohistochemical 
positivity for this protein. This finding was not systematically related to the presence of BCL2 
rearrangements, as in the majority of cases (32 out of 56, 57.14%) we observed discordant results 
between immunohistochemistry and FISH analysis (namely, 30 DLBCLs were BCL2-immunoreactive 
without showing concurrent BCL2 gene rearrangement and, vice-versa, 2 cases didn’t stain with anti-
BCL2 antibody but were positive by FISH). Among the 24 concordant cases, 20 turned out to be 
negative both for immunohistochemistry and FISH, whereas 4 were positive for both analyses.  On 
the other hand, MYC immunohistochemical expression was well related with cytogenetic data (p = 
0.02). In detail, 43 out of 54 cases (79,63%) were concordant (38 “double negative” and 5 “double 
positive); 7 were positive for immunohistochemistry but not at FISH analysis and 4 resulted 
cytogenetically rearranged without overexpression of MYC protein.  
Concurrent translocation of both BCL2 and MYC genes was present in a single DLBCL of the 
testis (double hit lymphoma), which also harbored MALT1 rearrangement. Thirteen lymphomas 
showed rearrangement of either BCL2 or MYC, whereas most patients (41/55, 74.5%) had no 
cytogenetic abnormality in the two genes. Immunohistochemical analysis of MYC and BCL2 
expression expanded the proportion of DLBCLs with identifiable double hit biology from 2% (patients 
with a cytogenetically defined DHL) to 15% (patients with an immunohistochemically defined double 
expressor lymphoma).  
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Correlation with clinical outcome 
Survival data were available for 103 patients and the median follow-up time was 37 months.      
Among clinical parameters, older age (>71 years), high IPI score (≥3) and high Ann Arbor stage (III-IV) 
were significantly related to unfavorable outcome (p = 0.04, p < 0.0001 and p = 0.0003, respectively).    
The whole series of EN DLBCLs did not show significantly different overall survival, when 
compared to the previously published nodal series (Uccella 2008). However, when the cases were 
subdivided according to the site of origin, significant differences emerged. In fact, we found that 
cutaneous and gastrointestinal DLBCLs had a better overall survival than nodal DLBCL, whereas 
cases involving immunological sanctuaries (CNS and testis) and the cervico-cephalic district 
demonstrated a worse outcome (p=0.0009) (figure 12).   
Among immunohistochemical markers, the expression of BCL2 and MUM1 carried a poor 
prognostic value (p = 0.0390 and p = 0.0035, respectively). MYC immunoreactive cases showed a 
trend to shorter OS. Univariate analysis showed patients in the DES 0 group to have better OS than 
patients in the DES 1 or 2 group. Interestingly, when applying the DES to patients with non-GC DLBCL 
or with low IPI scores (0 to 2), patients in the DES 2 group had inferior OS compared with patients in 
the DES 0/1 group. Conversely, DES was not prognostic in patients with GC DLBCL or high IPI score. 
GC subtype, as defined according to Hans’ algorithm, was significantly associated with longer OS 
compared with non-GC cases (p = 0.018) (figure 12).  
 At univariate analysis, the presence of one or more gene rearrangements was not associated 
with survival, as well as the presence of polyploid clones. The presence of rearrangements involving 
single genes (BCL2, BCL6, MYC, CCND1, BCL10 and MALT1) had no prognostic significance when 
considering the whole series. Only MYC translocation was associated with worse OS in 
gastrointestinal lymphomas (p = 0.008). The presence of either MYC or BCL2 rearrangement 
significantly predicted worse outcome in gastrointestinal DLBCLs (p = 0.02) but did not carry any 
prognostic value in the whole series (figure 12).  
Finally, multivariate analysis of the significant parameters revealed that the variables 
independently influencing OS were IPI score, the primary site of origin and MUM1 expression. 
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Figure 12. Overall survival according to clinical parameters, immunohistochemical and molecular cytogenetic results, and 
the site of origin. 
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BCL2 negative FL 
 
 
Clinico-pathological results 
The summary of the clinico-pathological results is reported in table 7. The mean age at 
diagnosis was 63.5 years (range 30-87 years). Thirty-two patients were males and 44 females.  
Most lymphomas in our series presented at advanced Ann Arbor stages III and IV (46/61, 
75.4%); in the remaining 15 cases (24.6%) the disease was confined to one side of the diaphragm and 
classified as stage I and II. Low FLIPI was observed in half cases (31/61, 50.8%), whereas intermediate 
and high scores were attributed to the remaining 16 (26.2%) and 14 (23%) patients, respectively.  
 
 Grade 1/2 
(51) 
Grade 3A 
(21) 
Grade 3B 
(4) 
Total  
(76) 
Age at diagnosis 
  mean value 
  range 
 
64.2 
44-87 
 
60 
30-87 
 
70.3 
60-81 
 
63.5 
30-87 
Gender 
  Male 
  Female 
 
21 
30 
 
9 
12 
 
2 
2 
 
32 
44 
Stage 
  I-II 
  III-IV 
  not known 
 
10 
30 
11 
 
4 
15 
2 
 
1 
1 
2 
 
15 
46 
15 
FLIPI 
  low 
  intermediate 
  high 
  not known 
 
21 
12 
7 
11 
 
10 
4 
5 
2 
 
0 
0 
2 
2 
 
31 
16 
14 
15 
 
Table 7. Clinico-pathological results of 76 FL. 
 
As far as geographical data are concerned, despite the great variability in birthplaces, analysis 
of migration flows from the early Seventies documented that most (70 out of 76, 92%) of our 
patients were either born in or moved early in their life to the Insubric region. This area is located on 
the southern side of the European Alps, between Lombardy (Italy) and Canton Ticino (Switzerland), 
and it is bordered by Lake Maggiore, Lake of Como and Lake of Lugano (figure 13). 
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Figure 13. Birthplace (a) and residency at diagnosis (b) of patients in our series, with focus on the Insubric region were most 
of them were born or moved early (c). Red tags represent cases without BCL2 translocation; green tags represent BCL2+ 
cases. Maps created with Google Maps. 
 
Morphological and immunohistochemical results 
All cases in our series had morphological and immunophenotypic features typical for FL, 
including growth pattern, admixture of centroblasts and centrocytes within neoplastic follicles, and 
germinal center phenotype. In detail, most of them (62/75, 82.3%) showed a follicular architecture, 
whereas the remaining were either follicular and diffuse (8/75, 10.7%) or predominantly diffuse (5/75, 
7%) (table 8). In one case we couldn’t properly define the architecture of the neoplastic proliferation 
due to the scarcity of biopsy material. 
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Table 8. Distribution of pattern of growth in our series of FL.  
 
Tumor grade defined according to the method of Mann and Berard (Mann 1982) was 
assessed for all FL cases, as well (table 9). Overall, in our cohort, low-grade (grade 1-2) FL 
represented approximately 2/3 of cases, and grade 3A-3B FL the remaining 1/3.     
 
 
Table 9. Grading of FL in our series, according to WHO classification. HPF: high power field of 0.159 mm² (40X objective). 
 
All cases expressed nuclear BCL6. The other germinal center associated protein, CD10, was 
detected in 68/76 FLs (89.5%). CD10-negative cases were equally distributed between low and high 
grade FLs, and all of them were positive for BCL2 immunostaining.  
Overall, BCL2 protein was expressed in 66/76 cases (86.8%). The proportion of BCL2 positive 
lymphoma cells ranged from 20% to 100%. In detail, the frequency distribution showed in only 2 cases 
a value <40%, whereas in most FLs 53/76 (69.7%) ≥80% of neoplastic cells stained with the anti-BCL2 
antibody. The cytoplasmic staining intensity of the tumor cells was compared with that of the 
admixed reactive T lymphocytes on the same slide and positive cases were classified into a 3-tiered 
score as follows: in 39/66 FLs (59.1%) tumoral B cells stained similar to reactive T cells and they were 
categorized as 3+; 10/66 FLs (15.1%) with weak immunostaining were classified ad 1+; 17/66 (25.8%) 
with intermediate intensity of BCL2 staining formed the 2+ subgroup (figure 14).  
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Figure 14. Evaluation of BCL2 intensity of staining with the anti-BCL2 (clone 124) antibody. 
 
A strong positive linear dependence between the proportion of positive cells and the intensity of 
immunostaining was observed (r = 0,75). In contrast, no relationship between FL grade and either 
intensity of BCL2 staining or percentage of positive lymphoma cells was found.   
Finally, as far as proliferation index is concerned, Ki-67 labeling index ranged from 6% to 70% 
(median value = 20%) and was <50% in all but three cases. Pearson linear correlation between Ki-67 
and other variables, namely histological grade and percentage of BCL2 positive cells was poor (r = 0.4 
and r = -0.2, respectively). Intriguingly, among pathological parameters, low proliferation index as 
assessed by Ki-67 rather than WHO-defined grade was related to BCL2 immunohistochemical 
expression (p = 0.02).  
 
Molecular cytogenetic results 
 
FISH on FFPE sections 
FFPE sections used for conventional histologic examination were available for all cases. 
Overall, BCL2 rearrangements were detected in approximately half of FLs in our series (39/76, 51.3%), 
independently from histological grade (table 10 and table 16). This observation was confirmed in a 
subset of 29 FLs enriched in BCL2-negative cases, which were investigated with an alternative BCL2 
break apart probe provided by Vysis (Abbott Laboratories, Abbott Park, IL, Usa) at the Cantonal 
Institute of Pathology, Locarno, Switzerland (table 16). 
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Table 10.  Comparison among histological grade, BCL2 rearrangements and polysomies. 
 
Even if most 3B FLs did not show BCL2 rearrangement, the sample size was too small to reach 
statistical significance. Polysomic cases were significantly prevalent among high grade FLs (p = 
0.002) (table 10). 
To further characterize BCL2 translocations and identify its partner, we used a commercial 
break apart probe targeting IGH. In most cases (66/76, 87%) these two molecular cytogenetic 
aberrations either coexisted or were both absent in the same sample, corroborating, although 
indirectly, either the presence or the absence of t(14;18). The ten discordant cases behaved as 
follows: 6 were IGH+/BCL2-, 3 were IGH+ in a percentage of neoplastic cells much higher than those 
carrying BCL2 rearrangement and 1 was IGH+ in a proportion of lymphoma cells much lower than 
those positive for BCL2 translocation (table 11). Such discordant cases were further investigated with 
break apart probes targeting BCL6 and MYC, since these genes are frequently involved in the 
pathogenesis and evolution of lymphoproliferative B cells disorders as IGH translocation partners. 
However, in only one of the 10 discordant cases we observed coexistence of IGH and BCL6 
rearrangements, suggesting the presence of a translocation involving these two genes.  
 
 
Table 11. Detail of 10 BCL2/IGH discordant cases, which were further analyzed for BCL6 and MYC translocations.  
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FISH on fresh frozen lymphoma samples 
In a subset of 32 cases, FISH experiments were replied on nuclei obtained from chromosome 
preparation of fresh lymphoma samples (table 16). Results were in agreement with those obtained 
on FFPE nuclei, with the exception of 3 cases. As detailed in table 12, these three discordant cases 
were BCL2-negative when analysis was performed on FFPE archived material, whereas turned out to 
be BCL2+ when the corresponding FL separated nuclei were investigated. However, in all 3 cases we 
were able to identify the possible reason why FISH analysis on FFPE sections did not identify BCL2 
rearrangement. Indeed, cases 33 and 68 showed only a minor percentage of translocated lymphoma 
nuclei on frozen samples. Moreover, in case 76, a “cryptic” BCL2 translocation characterized by an 
atypical breakpoint difficult to be identified on FFPE samples, was found.     
 
 
Table 12. Comparison between FISH experiments on FFPE and fresh frozen nuclei, with focus on discordant cases.  
 
 
Karyotype analysis 
We could perform karyotype reconstruction in a subset of 11 cases (figure 15 and table 13). 
 
 
 Figure 15. Patient N. 47: XX, t(14;18)(q34;q21) + der(18) t(14;18)(q34;q21). Karyotype reconstruction (left) and FISH analysis 
(right). The arrow indicates the normal copy of chromosome 18. The asterisk and the arrowhead show the derivative 
chromosomes.  
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Table 13. BCL2 rearrangements assessed on FFPE and fresh frozen nuclei and karyotype reconstruction in a subset of 11 
cases.  N.A. = not available 
 
Conventional cytogenetic analysis allowed us to gain a deeper insight into the pathogenesis of BCL2-
negative cases. In detail, in case 13 we detected the unbalanced translocation der(1q)t(1p;10), 
involving the 1p region where TNFRSF14 gene is located. Moreover, in two FLs (case 60 and 73), BCL6 
locus involvement at 3q27.3 was observed. Finally, case 64 deserves a particular mention, because it 
corresponds to a patient in which two synchronous lymphoproliferative B cell disorders were 
diagnosed, namely FL and in situ mantle cell neoplasia. In this case, karyotype reconstruction allowed 
us to identify t(11;14) between CCND1 and IGH genes, which is characteristic of MCL, together with 
t(2;18)(p11;q21) unbalanced translocation, involving BCL2 and an alternative partner, different from 
IGH, represented by the IGK gene. The analysis of such an unusual case became the object of a 
distinct paper published by our group (Vivian 2019, submitted) (figure 16). 
 
Case 
R-BCL2 
FFPE (%) 
R-BCL2 
fresh (%) 
Karyotype 
13 0% 0% 46,XX[4]/46,XX,+der(1q)t(1p;10)[7] 
17 20% 40% 46,XY 
18 90% 95% 46,X,+3,t(14;18)(q21;q32) 
20 60% 80% 46,XY,t(6;22)(p25;q12.1),t(14;18)(q32;q21) 
21 55% N.A. 47,XX,del(6)(q24qter),t(14;18)(q32;q21),+mar1[8] 
39 55% 66% 
46,XX,t(14:18)(q34;q21)[22] 
Nuc ish(BCL6X2)[100],(MYCX3)[71/100],(BCL2X2)(5'BCL2 
sep3'BCL2X1)[66/100] 
45 100% N.A. 47,XY,t(14;18)(q34;q21),+mar1 
47 100% 100% 
46 XX,t(14;18)(q34;q21)[3]/47 XX,t(14;18)(q34;q21),+ der(18) 
t(14;18)(q34;q21)[9]/47 XX,t(1;2)(p34;p21),t(14;18)(q34;q21)+ 
der(18)t(14;18)(q34;q21)[9] 
60 0% 0% 
46,XX,t(3;6)(q27.3;p22)[4]/46,XX,t(3;6)(q27.3,p22),+14[4].  
Ish t(3;6)(5'BCL6-,3'BCL6+; 5'BCL6+, 3'BCL6-).  
Nuc ish(BCL6X2)(5'BCL6 SEP 3'BCL6X1[33/150], 
(BCL2,MYCX2)[150] 
64 80% 71% 
46,XX[10]/46,XX,t(11,14)?del(11)(q11q22)[13]/49XXX, 
t(2;18)(p11;q21),+4,del(5)(q?),der(17)t(1;17)(q22-q25;q25), 
+der(18)t(2;18)(p11;q21)[23] 
73 0% 0% 
46,XY,del(3)(q27.3)(5'BCL6X1,3'BCL6X2)(5'BCL6, 
3'BCL6X1)[5/8],nuc ish(BCL2X2)[100] 
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Figure 16. Patient 64. Hematoxylin and eosin showing the coexistence of FL (red asterisk) and ISMCN (yellow asterisk) in 
the same lymph node (X40). The corresponding FISH analyses in the two components show BCL2 and IGH together CCND1 
rearrangements, respectively (X100).  
 
Comparison between immunohistochemical and 
molecular cytogenetic results 
As BCL2 gene rearrangement results in overexpression of the corresponding oncogene, we 
next analyzed the relationship between immunohistochemical and molecular cytogenetic data. 
Overall, 47/76 (61.8%) cases showed concordant results (p = 0.02), as detailed in table 14. 
 
 
Table 14. Comparison between FISH analysis of BCL2 rearrangement and BCL2 immunohistochemical expression. 
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Among the remaining 29 discordant cases (38,2%), only 2 were negative at immunohistochemistry in 
presence of BCL2 rearrangement as documented by FISH analysis, whereas most of them (27/29, 
93.1%) turned out to express BCL2 protein without the corresponding gene translocation. 
Interestingly, if we consider FLs with weak BCL2 immunostaing (i.e. 1+) the same way as negative 
cases, concordance between the two methods dramatically increases (p < 0.0001) (table 15).  
 
 
Table 15. Comparison between FISH analysis of BCL2 rearrangement and BCL2 immunohistochemical expression when 
grouping IHC1+ together with IHC negative cases. 
 
In detail, 9 out of 10 (90%) IHC1+ cases were concordantly negative at FISH analysis, suggesting that 
weak immunohistochemical expression of the BCL2 protein is not predictive of BCL2 chromosomal 
rearrangement. On the other hand, approximately one half (9/17, 52.3%) of IHC2+ cases and one 
quarter (9/39, 23.1%) of IHC3+ cases were FISH-, suggesting that BCL2 protein overexpression can be 
due to alternative mechanisms, different from gene translocation. 
 
Correlation with clinical data and outcome 
We found both BCL2 immunohistochemical expression and rearrangement to be significantly 
prevalent in patients with high Ann Arbor stage disease (p = 0.023 and p = 0.026, respectively), 
whereas no correlation was observed between BCL2 status and FLIPI.  
Survival data were available for 61 patients and the median follow-up time was 52 months 
(range 12-273). Overall, only 7 patients died (11.5%), whereas most of them (88.5%) were alive at latest 
follow-up. Among clinical parameters, older age (>7o years), was significantly related to unfavorable 
outcome (p = 0.005), whereas high FLIPI score showed a trend towards statistically significant poor 
prognosis (p = 0.09). 
 
 
 
 
                                                                                                                         RESULTS 
 
    
 
 
 
46 
Case 
BCL2 
IHC 
R-BCL2  
FFPE (%) 
R-BCL2 
fresh (%) 
1 95% 80% N.A. 
2 80% 70% N.A. 
3 100% 70% N.A. 
4 50% - N.A. 
5 80% - N.A. 
6 90% - N.A. 
7 100% 70% 92% 
8 80% - N.A. 
9 100% 70% 69% 
10 - - N.A. 
11 20% - N.A. 
12 90% - - 
13 50% - - 
14 100% 100% 100% 
15 100% 36% N.A. 
16 - 100% N.A. 
17 90% 20% 40% 
18 75% 90% 95% 
19 70% - - 
20 100% 60% 80% 
21 100% 55% N.A. 
22 100% 70% N.A. 
23 100% 80% 75% 
24 100% - - 
25 70% - - 
26 100% - N.A. 
27 100% 60% 24% 
28 100% 100% N.A. 
29 - - - 
30 - - - 
31 90% 70% 50% 
32 60% - N.A. 
33 90% - 28% 
34 90% 80% N-A- 
35 30% - - 
36 - - N.A. 
37 100% 70% N.A. 
38 90% - N.A. 
39 100% 55% 66% 
40 - - N.A. 
41 100% - N.A. 
42 90% - N.A. 
43 80% 85% N.A. 
44 100% 85% 50% 
45 90% 100% N.A. 
46 pos - N.A. 
47 100% 100% 100% 
48 pos 90% N.A. 
49 100% - N.A. 
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                                           Table 16. Comparison between immunohistochemical and FISH results.  
                   Cases also investigated at the Cantonal Institute of Pathology, Locarno, are highlighted in light blue. 
50 40% - N.A. 
51 90% 100% N.A. 
52 90% - N.A. 
53 - - - 
54 - 100% N.A. 
55 100% 100% N.A. 
56 90% 80% N.A. 
57 100% 90% N.A. 
58 70% - N.A. 
59 80% - N.A. 
60 70% - - 
61 100% 70% N.A. 
62 100% 25% N.A. 
63 100% 100% N.A. 
64 100% 80% 71% 
65 80% 70% N.A. 
66 - - - 
67 - - N.A. 
68 70% - 14% 
69 80% 50% N.A. 
70 pos 100% N.A. 
71 80% - N.A. 
72 100% 70% N.A. 
73 100% - - 
74 95% 80% 100% 
75 80% - - 
76 100% - 60% 
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Personalized medicine is defined by the National Institute of Health (NIH) as a form of 
medicine that uses information about a person’s genes, proteins, and environment to prevent, 
diagnose, and treat diseases. This term was used for the first time in the way it is meant today on The 
Oncologist twenty years ago (Langreth 1999). Since then a plethora of biomarkers have been 
investigated in all cancer fields, both to clarify details regarding the pathogenetic mechanisms 
underlying neoplastic transformation and for practical purposes. However, it is crucial to understand 
when and how they can be integrated into the clinical setting, translating experimental results from 
bench to bedside, with the aim of improving patients’ care.  
B cell lymphomas (BCLs) represent a wide group of neoplasms whose categorization 
continues to evolve in parallel with the knowledge of their molecular landscape and their presumed 
cell of origin.  Particularly, DLBCL and FL are the most common types of NHL worldwide (WHO 2017) 
and still represent a challenge for both researchers and clinicians. The research work along the three 
years of this PhD program has been focused on the molecular genetic characterization of these two 
groups of lymphomas and the results have been integrated with morphological, 
immunohistochemical and available clinical data.  
 
* * * * * * 
 
 
DLBCL category encompasses a heterogeneous group of aggressive BCL and currently, many 
clinicopathologic variants and distinct subtypes are recognized, although they account for only a 
minority of all cases. The remaining ones are referred to as DLBCL, not otherwise specified (WHO 
2017). In contrast to indolent lymphomas, the survival curve typically shows an initial downward 
slope followed by a plateau, indicating the potential curability of a significant proportion of patients 
who achieve remission. In DLBCL, GEP analyses have identified two main biologic subtypes - GCB and 
non-GCB (Alizadeh 2000). This information has become more and more clinically relevant, as drugs 
that are expected to benefit one subtype or the other have been developed, such as ibrutinib, a 
selective, irreversible inhibitor of Bruton’s tyrosine kinase, that is typically expressed in non-GCB 
cases. Another point is represented by so called double hit (DH) lymphomas. These high-grade 
lymphomas are strictly defined by the presence of two genetic abnormalities, namely 
rearrangements involving both MYC and BCL2 and/or BCL6, and it’s important that they are 
appropriately identified as they seem not to respond well to the current standard treatment for 
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DLBCL, NOS. Moreover, studies focusing on DLBCLs arising in several EN locations have suggested 
the existence of peculiar site-related molecular, pathological and clinical characteristics, with 
therapeutic and prognostic consequences (Møller 2004, Al-Humood 2011, Raghoebier 1991, Kramer 
1998, Lal 2008, Jang 2011). Although DLBCL arising in specific EN sites have been classified by WHO as 
separate entities, such as CNS and cutaneous DLBCL, the significance of the primary EN origin itself 
has been poorly addressed.  
The aim of the first part of our project was to investigate the clinico-pathologic, 
immunophenotypical and cytogenetic features of a series of 106 EN-DLBCLs, and to compare the 
obtained data to the available survival information.  As only a subset of 58 cases in our series were 
cytogenetically investigated for the detection of MYC, BCL2 and BCL6 chromosomal rearrangements, 
we have used the generic term “DLBCL” throughout the manuscript to address diffuse aggressive 
lymphomas with DLBCL morphology. In fact, even if we have not excluded the possibility of 
double/triple hit in all the series, it is also true that in the cytogenetically investigated subset we 
found only one double hit lymphoma out of 58 cases (1.7%). Thus, it is reasonable that the vast 
majority of our cases belong to the DLBCL, NOS category, and the results obtained in our series can 
be extended to this group of neoplasms with little statistical effect.  
The analysis of our results highlighted several features that seemingly delineate a specific 
profile for EN DLBCL, either as a group, or with reference to specific primary sites. From a clinical 
point of view, patients in our series presented most frequently with low or low-intermediate IPI 
score and early stage disease, as previously observed in large population-based studies on EN DLBCL 
from both the United States and Asia (Castillo 2014, Lal 2008). By contrast, in a series of primary 
nodal DLBCLs previously published by our group, we found a prevalence of advanced-stage diseases 
(Uccella 2008). We can hypothesize that site related symptoms associated with the tumor mass 
effect may contribute to early detection of the disease in primary EN DLBCLs. The 
immunohistochemical study firstly focused on the application of the Hans’ algorithm for the 
identification of the cell of origin. Considered as a group, the majority of our EN DLBCL belonged to 
the non-GC subtype, as it was recently observed by Wang and coworkers (Wang 2016). However, in 
other unselected series, there were no differences in the frequencies of GC and non-GC cases 
between primary nodal and EN DLBCLs (Kim 2011). Such conflicting results may be due to several 
causes. First, the definition itself of a lymphoma as primary nodal or EN is still a controversial issue, 
particularly in cases of disseminated disease or involvement of peculiar sites, such as Waldeyer’s ring, 
spleen and bone marrow (Krol 2003). In our study, we excluded cases arising in the spleen, in the 
tonsils and in the thymus, restricting the definition of “extranodal” to “extralymphoid” sites. 
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Second, immunohistochemical algorithms alternative to the Hans’ one have been used in different 
studies, and this may affect the accuracy in defining the cell of origin (López-Guillermo 2005, Al-
Humood 2011). Third, the adoption of different inclusion criteria, which may privilege peculiar sites 
and exclude some others, has introduced an important selection bias. In our series there is 
enrichment in testicular and CNS cases, which are predominantly of non-GC type, and this fact may 
have influenced our results.  
When we separately looked at the various EN sites we found significant differences among 
them. Among digestive cases, most of the intestinal DLBCLs belonged to the GC subype, whereas 
gastric DLBCL were equally distributed between GC and non-GC, supporting the hypothesis that 
gastric and intestinal DLBCLs may recognize different pathways of lymphomagenesis (Connor 2007, 
Mitchell 2008). On the other hand, the majority of DLBCLs arising in immunological sanctuaries (CNS 
and testes) displayed a non-GC phenotype, confirming previous findings (Magnoli 2015 Al-Abbadi 
2006, Booman 2008, Li 2010, Gill 2014). Interestingly, all the cervico-cephalic lymphomas investigated 
in our study belonged to the non-GC group. It is worth noting that, in our series, this group included 
DLBCL of the nose, paranasal sinuses and pharynx, whereas other studies focusing on H&N 
lymphomas included patients diagnosed with primary DLBCLs of the Waldeyer’s ring (i.e. palatine 
tonsil, lingual tonsil and nasopharynx), which were predominantly of GC subtype (Lopez-Guillermo 
2005, de Leval 2012).  
We next moved to the immunohistochemical analysis of BCL2 and MYC expression. 
Intriguingly, we found the highest proportion of double expressor (DE) DLBCL among lymphomas of 
the cervico-cephalic district. The majority of our DLBCLs in this site presented with low or low-
intermediate-risk IPI score and early-stage disease, all of them were attributed a non-GC phenotype, 
and, as a group, they had a poor outcome, in agreement with the reported adverse prognostic value 
of concomitant expression of BCL2 and MYC (Kramer 1998, Sarkozy 2015, Sohn 2003, Swerdlow 
2014).  
Molecular cytogenetic analysis using FISH technique with break-apart probes allowed us to 
investigate abnormalities, including rearrangements and copy number alterations, of key genes in 
lymphomagenesis. Considering the whole series, BCL6 was the most commonly rearranged gene, 
followed by MYC and BCL2. These results were different from those that we previously observed in a 
series of 74 primary nodal DLBCL (Tibiletti 2009), in which BCL6 was the most frequently rearranged 
gene, as well, but MYC alterations were present in a minority of cases, whereas rearrangements of 
BCL2 and BCL10 were more frequent than in the present series of EN DLBCL. The involvement of MYC 
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alterations in lymphomagenesis is known to be related to an increased biological aggressiveness of 
the neoplasm. A recently published FISH study by Quesada et al (Quesada 2017) reported increased 
MYC copy number in more than 10% of de novo DLBCL, claiming a relationship with a worse patients’ 
outcome. However, the authors did not provide details on whether the increased copy number was 
attributable to polysomy of chromosome 8, or to an amplification of the gene locus. In our series, we 
observed true amplification of MYC locus in only 3 gastrointestinal DLBCLs (5.2%). Interestingly, in 
two of these cases, MYC amplification was associated with MYC rearrangement and the patients had 
a dismal outcome, as they died of disease 1 and 5 months after the diagnosis, respectively. Whilst the 
negative prognostic impact of MYC rearrangements seems to be well established, the clinical 
implications of extra copies of the gene are less clear. In the largest reported series of DLBCLs with 
MYC amplification, the authors concluded that MYC increased copy number was not predictive for 
inferior survival (Landsburg 2016). Similarly, results from a European series suggested that the 
detection of extra copies of MYC was not related to worse prognosis in the absence of concurrent 
del(8p) (Testoni 2011). In line with these data, we can state that in our patients with MYC 
amplification, a dismal outcome was observed only in the presence of concurrent MYC 
rearrangement. However, according to other authors, the presence of both MYC translocations and 
gains is associated with a poorer outcome (Yoon 2008). Taken together, these data suggest that 
larger series of patients would need to be studied to determine the prognostic significance of MYC 
amplification. Only a single case in our series, arising in the testis, could be defined as DH, bearing 
concomitant MYC and BCL2 rearrangements.  
Interestingly, in this study, we identified 17 cases showing small rearranged clones and, in the 
majority of them, the small clones coexisted with major rearranged clones. This peculiar cytogenetic 
condition could suggest the predisposition to double strand breaks and, consequently, a possible 
prognostic effect. However, the clinical behavior of this condition is still unknown.  
A significant heterogeneity in the type and frequency of gene rearrangements was observed 
among DLBCLs arising in different body sites, paralleling immunohistochemical results and further 
supporting the existence of site-specific pathogenetic mechanisms. In fact, BCL6 was frequently 
rearranged in testicular DLBCL, whereas intestinal DLBCLs showed a preferential rearrangement of 
MYC. Strikingly, CNS DLBCL showed very few rearrangements of the investigated genes, with a major 
clone of cells with BCL6 rearrangement in only one case. This suggests that other mechanisms of 
lymphomagenesis exist in this site, and further supports their separation from DLBCL-NOS. Indeed, 
several years ago, another FISH analysis of the genes classically involved in lymphomagenesis (BCL2, 
BCL6 and MYC), in a series of 13 cerebral DLBCL, showed the presence of BCL6 rearrangement in only 
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three cases, with no other gene abnormalities (Montesinos-Rongen 2002). The involvement of non-
classical BCL6 locus alterations has also been reported in CNS DLBCL by Schwindt and coworkers, 
who suggested that they may be explained by aberrant class switch recombination or somatic 
hypermutation, which supported the origin of CNS DLBC from late germinal center cells (Schwindt 
2006). More recently, other studies evaluating large numbers of primary CNS DLBCLs have 
confirmed that BCL2, BCL6 and MYC rearrangements are rarely seen in this entity (Nosrati 2019, Villa 
2019). When we looked at the cell of origin, 38 out of the cytogenetically investigated cases 
belonged to the non-GCB group and were characterized by a high frequency of BCL6 
rearrangements, together with a significant proportion of aberrations in multiple genes, supporting 
the concept of a genetically unstable and heterogeneous entity. By contrast, the 20 GC cases 
preferentially showed BCL2 rearrangements. This and other genomic differences have been already 
described in DLBCLs and support the view that GC and non-GC lymphomas are biologically distinct 
entities with different pathogenetic pathways (Nedomova 2013, Pasqualucci 2015). However, in the 
case of EN DLBCL, if we consider the different distribution of GC and non-GC subtypes in the various 
primary EN sites, we could assume that the different genomic profiles observed between nodal and 
EN-DLBCLs may be influenced by the primary site of origin, rather than exclusively depending on the 
cell of origin, as suggested by others (Al-Humood 2011).  
The survival analysis of our series had unavoidable limits due to different therapeutic 
approach to DLBCLs involving specific body sites. Nevertheless, it has still been performed, only 
considering OS, to provide a general overview on the outcome of the patients with EN DLBCLs. OS is 
the best-established primary efficacy end point to evaluate DLBCL therapies, however progression-
free and disease-free survival represent other important clinical parameters when evaluating the 
natural history of the disease. These parameters were not included in our analysis, as they were 
available only for a limited number of patients. Thus, in our minds, our survival analysis does not 
provide robust clinical indications, but it can give clues to the relevance of some biologic mechanisms 
involved in lymphomagenesis. Further controlled studies are needed to confirm our findings. The 
Cox’s regression model did not show any significant difference in patients’ outcome between the 
whole series of EN-DLBCL and the nodal series previously investigated by our group (Uccella 2008). 
However, when considering the specific site of origin, a statistically significant difference in terms of 
OS emerged among DLBCLs arising in different organs and tissues. In detail, cutaneous lymphomas 
showed, as expected, the best prognosis, followed by DLBCLs arising in the GI tract and by nodal 
cases. Finally, a dismal outcome was observed in lymphomas affecting the head and neck district and 
the immune-privileged sites. At multivariate analysis, the primary site of origin was one of the 
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variables independently influencing OS, together with IPI score and MUM1 expression. In line with 
the observation of Hans and coworkers, MUM1 turned out to be an independent risk factor (Hans 
2004). The prognostic value of the Hans’ algorithm was evident only if applied to the whole series, 
but not when considering the various sites separately, possibly due to small sample size. Other 
immunohistochemical markers related to worse survival were BCL2 and MYC. Furthermore, we 
confirmed that the combination of increased MYC protein, implying accelerated proliferation, with 
the expression of anti-apoptotic BCL2 factor, is a predictor of dismal prognosis in DE lymphomas. 
Most retrospective studies suggest that DH and DE lymphomas carry a poor prognosis when treated 
with conventional therapeutic regimens, such as R-CHOP. However, there is a clear need for further 
prospective studies to clarify the true prognostic value of these parameters, as the role of the two 
genes has been recently challenged in a large randomized trial by the GELA/LYSA consortium (Copie-
Bergman 2015). We previously demonstrated that the presence of at least one gene rearrangement 
was associated with a worse outcome in nodal DLBCLs (Tibiletti 2009). In contrast, cytogenetic 
abnormalities did not carry prognostic significance when considering the whole EN series. In fact, 
only MYC translocation was related to shorter OS, but only in the gastrointestinal subset. It is 
conceivable that in peculiar EN location, such as, for example, CNS lymphomas, which bear a 
significantly low proportion of abnormalities in the investigated genes, the drivers of 
lymphomagenesis and of the aggressive behavior are genomic alterations different from the genes 
rearrangements classically involved in nodal DLBCLs. In a series of testicular DLBCLs we observed 
that both the amounts of the T-cell infiltrate and its composition seem to be related to patients’ 
outcome (Magnoli 2015). Thus, it is conceivable that the composition of the microenvironment is one 
of the factors playing a major role in affecting the biology of the tumor, particularly in immune 
sanctuaries, where lymphomatous B cells and reactive inflammatory cells may establish peculiar 
interactions between each other. In conclusion, our results seem to suggest that the primary site is 
related to the peculiar immunophenotypic and genetic features of EN DLBCLs and strongly 
influences the natural history of the disease and the patients’ outcome. Hence, this study provides 
further support to the existence of site-related mechanisms of lymphomagenesis, as also proposed 
by others (Lopez-Guillermo 2005, Castillo 2014, Wang 2016, de Leval 2012, Olszewski 2014).    
Our results outline that both immunohistochemical and FISH approaches are needed to 
improve the detection rate of aggressive EN-DLBCL including DE and DH cases. Studies on large and 
well characterized series of EN DLBCLs are required to shed light on the complex interaction 
between the intrinsic biomolecular features of these heterogeneous diseases and the surrounding 
macro-/microenvironment, in the need to develop more effective site specific therapeutic strategies. 
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* * * * * * 
FL has long been considered a well defined disease, with straightforward diagnostic criteria, 
a clear genetic background and recognizable precursor condition. In the last few years, a deeper 
insight in the clinicopathological features of FL has unveiled that this disease is, in fact, composed of 
many different entities, which raised the need of personalized diagnostic and therapeutic 
approaches. Such heterogeneity has been at least partly acknowledged by the inclusion of four 
clinicopathological variants of FL in the latest update of the WHO classification (WHO 2017), namely 
in situ follicular neoplasm, duodenal-type FL, testicular FL, ad diffuse FL. In addition, separate 
entities, such as pediatric-type FL, large B-cell lymphoma with IRF4 rearrangement, and primary 
cutaneous follicle center lymphoma have been recognized. However, besides these well-defined 
entities, other aspects of the inter- and intra-tumor heterogeneity of FL are evident. In particular, the 
analysis of the genetic profile of tumor cells highlights important relationships between specific 
genetic lesions and tumor initiation, progression, and transformation. Since the discovery of BCL2 
gene by Tsujimoto et al (Tsujimoto 1984), the translocation (14;18)(q32;q21) has been considered the 
genetic hallmark of FL. In recent years, it has been recognized that FL lymphomagenesis is a 
multistep process, in which early lesions progress to overt disease through complex events of 
selection/counter-selection. Using an exome sequencing approach, Green and coworkers proposed 
an elegant genetic evolution model for FL tumorigenesis in which founder mutations turn a non-
malignant B cell clone into a premalignant tumor cell population, stable enough to acquire one or 
more secondary driver mutations, leading to an early malignant clone. Finally, tertiary mutations may 
either act as passenger or accelerator mutations, the latter providing a selective advantage to a 
progressed malignant subclone (Green 2013). At the beginning of this spectrum, the earliest known 
oncogenic event is the t(14;18)(q32;q21), and it is reported with a prevalence of 85-90% in most of the 
published literature (WHO 2017). However, detection of t(14;18) is not required for the diagnosis of 
FL, even if it can be a useful tool, when present, in small biopsies and atypical lymphoid 
proliferations, in the context of equivocal morphologic and immunophenotypic findings. As a 
consequence, most centers do not perform routine evaluation of BCL2 status, so that they do not 
know the exact incidence of t(14;18) in their series. Moreover, some authors have observed a 
proportion of BCL2-negative FLs as high as 50% in their series, and, in general, reported detection 
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rates are significantly lower in Far East and, to a less extent, European studies, compared to the US 
ones (Pezzella 1990, Biagi 2002, Pan 2012, Segel 1998).  
Daily diagnostic activity in our pathology department seems to confirm the latter 
observations, challenging the paradigm of BCL2 translocation as a necessary early event in FL 
pathogenesis and suggesting the existence of marked geographical differences in the pathogenesis 
and of alternative mechanisms of genetic deregulation in BCL2-negative cases. Starting from this 
practical observation, the aim of the second part of our project was to test the incidence of BCL2-
negative FLs in a series of Italian patients from the Insubric region, evaluate its association with 
clinicopathological features and investigate alternative genetic aberrations in this subset.  
Epidemiological features of our series were in line with published literature (WHO 2017), as 
our patients were adults with a median age in the sixth decade of life and females were slightly more 
common involved than males. Overall, BCL2 rearrangements were detected in approximately half of 
our cases (39/76, 51.3%), in contrast with the 85-90% rate reported in most series (WHO 2017). It can 
be hypothesized that such discrepancy depends on the demographic characteristics of our patients, 
which were either born in or moved early in their life to the Insubric region. Indeed, NHL incidence 
widely vary across Italy, and our territory is among the areas with the highest recorded rates (AIRT 
working group 2006) (figure 17).   
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Figure 17. Non-Hodgkin lymphomas prevalence in Italy by macro-area (proportion per 100.000) and incidence by sex and 
micro-area.   
It is conceivable that environmental factors may operate selectively in different geographical 
districts, favoring lymphomagenesis and resulting in FLs that are morphologically similar but 
molecularly distinct. This point has already been addressed to in previous studies, however, the 
authors concluded that the large variance in the detection frequencies of t(14;18) depended on 
methodological limitations (Albinger-Hegyi 2002, Aster 2002). These considerations, however, 
referred to the use of standard PCR conditions with major breakpoint region (MBR)/minor cluster 
region (mcr)-specific primer pairs, that indeed render false negative results when rearrangements 
involve BCL2 sequences outside of the MBR and mcr. As a high fraction of rearrangements fall 
outside these regions (Akasaka 1998, Albinger-Hegyi 2002), the authors optimized long-distance PCR-
protocols that offered some significant advantages in terms of sensitivity over the more commonly 
used standard methods. Interphasic FISH has a higher overall diagnostic sensitivity than PCR, 
because the FISH probes span almost all breakpoints. In addition, they do not require absolute 
sequence complementarity and are not as adversely impacted by poor quality of DNA specimen. 
Finally, FISH can also detect complex cytogenetic abnormalities and translocations involving the IGH 
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or BCL2 genes. It is true that some cytogenetic changes may still be missed by FISH analysis, such as 
translocations between BCL2 gene and unusual partner or cryptic translocations not detected by 
commercially available probes, however these represent rare occurrences (Godon 2003, Bentley 
2005). We tested different commercially available probes for BCL2 translocation, obtaining 
overlapping results in terms of percentage of translocated cases lower than expected. Moreover, as 
we had also the opportunity of performing karyotype analyses on a consistent number of our cases, 
we demonstrated that chromosome abnormalities other that t(14;18) can be present in FL. As a 
whole, these observations tend to confirm that the variation in the incidence of t(14;18) across 
studies may be due to geographical factors rather than technical problems. The relative lower 
incidence of FL registered in Asian populations seems not to correspond to a lower frequency of 
BCL2 rearrangements in healthy individuals (Biagi 2002). Moreover, epidemiological data derived 
from Asian emigrants to the United States and their descendants seem to imply environmental 
rather than genetic influences (Herrinton 1996). For example, cigarette smoke and pesticide 
exposure have been called into question (Biagi 2002), but the precise nature of such putative factors 
is far from being elucidated. 
After assessing the percentage of BCL2-rearranged cases, we systematically searched for 
translocations involving its classical partner, IGH. While all BCL2+ FLs showed concurrent IGH 
rearrangement, the opposite was not true, as we found 6 IGH+/BCL2- cases. Moreover, in 4 additional 
cases we observed discordant results, as rearrangements in both genes were present, but with quite 
different percentages of translocated cells. These 10 cases were tested with break-apart probes for 
BCL6 and MYC genes, due to their pivotal role in the pathogenesis and evolution of 
lymphoproliferative disorders. As we found only BCL6 translocation in a single case, further 
investigations are required to clarify the molecular genetic background of the remaining 9 discordant 
FLs.  
In a subset of 32 cases, the availability of fresh lymphoma samples allowed us to confirm data 
obtained on FFPE material, but at the same time highlighted the limits of FISH analyses on archived 
material. Indeed, we observed three discordant cases which were BCL2-negative when analysis was 
performed on FFPE samples, whereas turned out to be BCL2+ when the corresponding fresh frozen 
nuclei were investigated. If it is true that the preservation of histological context in paraffin sections 
allows for the analysis of the topographical distribution of cytogenetically abnormal cells, FISH on 
isolated nuclei from FF tissue was able to detect either small neoplastic clones or an atypical BCL2 
breakpoint due to its major sensitivity.  
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Besides confirming FISH results, karyotype analyses proved that chromosome abnormalities other 
that t(14;18) could characterize FL. In detail, BCL6 locus on 3q was involved in two cases. BCL6 gene 
encodes a transcriptional repressor whose oncogenic effect is well-recognized (Albagli-Curiel 2003, 
Saito 2007). BCL6 rearrangements have been variously reported as transforming and proliferating 
stimuli alternative to the classic BCL2 deregulation in high grade FL (Guo 2005, Katzenberger 2004) or 
in low grade disease (Marafioti 2013). Others again have challenged its putative role as a crucial 
pathogenetic factor in BCL2-negative FL, suggesting that BCL6 amplification/3q27 gain is associated 
with peculiar clinicopathologic characteristics, namely, high grade morphology, high BCL2 and MUM1 
protein expression and frequent combination with BCL2 gene amplification/18q21 gain (Karube 
2008). Moreover, in one FL we observed an unbalanced translocation involving TNFRSF14, a member 
of the TNF-receptor superfamily with tumor suppressor function which encodes the herpes virus 
entry mediator (HVEM). Disruption of the HVEM-BTLA (B and T lymphocyte attenuator) axis has 
been documented during the early stages of GC lymphomagenesis (Boice 2016). Katzenberger and 
coworkers identified a distinctive subtype of t(14;18)-negative FL, characterized by a predominantly 
diffuse growth pattern, localized involvement of inguinal lymph nodes and 1p36 deletion 
(Katzenberger 2009). Aberrations of this chromosomal region have been reported in BCL2- 
morphologically classical FL with a predominantly follicular growth pattern, but it should be noted 
that they represent one of the most common alteration in classical BCL2+ FLs too (Launay 2012, 
Kridel 2012). Finally, we observed a translocation in which the fusion partner of BCL2 was represented 
by the lambda light-chain gene (IGL). Variations in the t(14;18) can be classified into two categories: 
simple variants, involving chromosomes 18 and 2, or 22, in which the fusion partner of BCL2 is a light-
chain gene and complex variants, occurring among chromosomes 14, 18 and other chromosomes. 
Both represent rare events, reported as single cases or small series in the literature (Bentley 2005, 
Impera 2008). Taken together, these observations do not shed light on the pathogenesis of BCL2- FLs 
but suggest the existence of diverse mechanisms of genetic deregulation, which in many cases have 
not been elucidated, yet.   
Another point of interest is represented by the correlation between molecular cytogenetic 
and immunohistochemical results. All FLs with weak or absent BCL2 staining were negative at FISH 
analysis, with the only exception of 2 cases. This result minimizes the need for testing additional 
antibodies in the work-up of suspected FLs that are negative with one immunostaining, as suggested 
by other authors (Xerri 2016). On the other hand, nearly half of cases with moderate to intense BCL2 
staining did not show t(14;18). This phenomenon is well documented in the literature and attributed 
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to the existence of alternative mechanisms leading to protein overexpression, such as amplification 
of chromosome 18 which may implicate an increased dosage effect (Falini 2002, Horsman 2003).  
In our study, BCL2 immunohistochemical expression and intensity of staining, as well as the 
presence or absence of IGH/BCL2 fusion were not significant prognostic indicators of OS. Conflicting 
results have been published on the prognostic significance of BCL2 status in FL, mostly based on 
small series of cases with relatively short follow-up periods. Although in an old study t(14;18) was 
associated to poor response to therapy and short survival (Yunis 1989), in the same period other 
authors observed no difference in prognosis between cases with and without the translocation 
(Levine 1988) and this observation was confirmed in subsequent years (Pezzella 1992, Maeshima 
2013). Overall, it seems that there are no grounds for considering BCL2 status to be a useful 
prognostic marker in clinical practice. However, as testing for t(14;18) is currently asked by 
hematologists to monitor response to therapy and detect recurrent disease, it becomes crucial to 
investigate BCL2 rearrangement already at diagnosis, as the rationale behind this request fails in the 
presence of BCL2-negative FLs. Given its superior diagnostic sensitivity, FISH represents the front-line 
molecular test for t(14;18). PCR analysis is faster, less expensive to perform and has greater analytic 
sensitivity than FISH. However, this latter is not ordinarily required at the time of initial diagnosis, 
when lymphoma cells tend to be abundant, but becomes crucial in the setting of disease revaluation.  
In summary, our results indicate that BCL2 rearrangement in FL is not as frequent as 
previously reported, and its presence should not be taken for granted, with important consequences 
on both the diagnosis and follow up of the patients. It becomes evident that the genetic landscape 
of FL is more complex than previously thought and that other alternative genetic abnormalities may 
trigger the pathogenesis of this lymphoma (Magnoli 2019). Studies on larger and well characterized 
series of BCL2-negative FLs are required to identify their pathogenesis and molecular background in 
order to clarify their biological significance and to properly manage patients.   
 
 
* * * * * * 
In conclusion, what we learned from our studies is that even within an individual clinico-pathological 
entity, there is considerable heterogeneity with respect to genetic alterations, expression of 
commonly assayed markers and, most important, clinical outcome. Even if classification schemes are 
essential frameshift for the patients’ management, we are not dealing with monolithic entities at all, 
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but rather puzzle pieces which only assembled together allow us to properly understand diseases 
and treat our patients. The personalized approach acknowledges this complexity and gives us tools 
for the continuous improvement of patients’ care. 
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